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The Road goes ever on and on 
Down from the door where it began. 
Now far ahead the road has gone, 
And I must follow, if I can, 
Pursuing it with weary feet, 
Until it joins some larger way, 
Where many paths and errands meet. 
And whither then? I cannot say. 
 
J.R.R. Tolkien, The Lord of the Rings 
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ABSTRACT 
 
Chikungunya virus (CHIKV) is an arbovirus spread by the Aedes sp. of mosquitoes. 
Chikungunya fever results in a sudden onset of a febrile disease with headache, 
nausea and maculopapular rash. Additionally, a large proportion of the affected 
individuals experience persistent arthralgia months after all other signs of the 
disease have vanished. Originally discovered in Tanzania in 1952, it re-emerged 
with a massive outbreak in several islands of the Indian Ocean in 2004 and spilled 
over onto the Indian sub-continent and South-east Asia. Later CHIKV invaded 
Southern Europe and since the last two years has ventured into the western 
hemisphere, causing more than 1 million suspected infections in the Caribbean 
islands, Central and Latin America. The explosive nature of these outbreaks has led 
to a tremendous strain on the public health system of many of the affected 
countries already burdened with the endemically circulating Dengue virus. 
 
So far, no licensed vaccines or antivirals exist to counter this virus. Besides, it is 
paramount to have an in-depth understanding of the replication mechanisms of 
this re-emerging pathogen in order to come up with novel and effective therapeutic 
measures. A previously characterized CHIKV replicon cell line was used to conduct 
a high-throughput screen of ~3000 bioactive compounds, which are in clinical use 
or in clinical trials against other diseases. This led to the discovery of abamectin, 
ivermectin and berberine as novel antivirals effective at low micromolar 
concentrations and having broad-spectrum anti-alphaviral activity. 
 
Deciphering the mode of action of berberine led to the discovery that CHIKV 
infection robustly activates the three main branches of the mitogen-activated 
protein kinase (MAPK) signaling – extracellular signal regulated kinase (ERK), p38 
MAPK and c-Jun NH2-terminal kinase (JNK). Berberine was shown to reduce this 
virus-induced MAPK activation and also suppressed virus-independent ERK 
activation. These pathways were shown to be important for CHIKV replication, as 
specific inhibitors of the ERK and JNK pathways significantly reduced the viral 
progeny release. Most importantly, berberine reduced CHIKV-induced 
inflammatory disease in a mouse model and is one of the few compounds reported 
to show in vivo efficacy. 
 
Exploring the antiviral mechanism of obatoclax, an anticancer compound 
previously reported to be active against different viruses, including influenza A 
virus and Sindbis virus, revealed the compound to be active against other 
alphaviruses, including SFV and CHIKV. Further characterization showed that 
obatoclax inhibits viral fusion by rapidly neutralizing the acidic environment of 
endolysosomal organelles. Additionally, characterization of escape mutants 
showed that a single mutation in the SFV E1 fusion protein was sufficient to confer 
partial resistance against obatoclax. 
 
This study has unearthed effective candidate antivirals against alphaviruses, which 
have served as useful tools to help us gain further insight into alphavirus biology, 
when characterizing their modes of action.  
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1. INTRODUCTION 
 
Viruses that are spread to a mammalian host through a hematophagous (blood-
feeding) arthropod vector are called arboviruses (ARthropod-BOrne viruses). 
Mainly spread by mosquitoes, ticks, midges and sandflies (common arbovirus 
vectors are shown in Fig. 1), these viruses are usually maintained in nature 
through transmission cycles between the arthropod vector and a vertebrate animal 
reservoir. Humans are primarily accidental dead-end hosts in the majority of the 
transmitted arboviruses, but viruses like dengue and chikungunya are also spread 
through a man-mosquito-man urban transmission cycle (2, 3).  
 
Since the advent of the exploration age and the slave trade, vector mosquitoes 
were disseminated to different corners of the world. Sporadic outbreaks of dengue 
and yellow fever were on the rise in tropical areas of Africa and the Americas. It 
was only in the beginning of the 20th century that the Aedes aegypti mosquito was 
implicated as the vector for Yellow fever. This was due to the ingenuity of Carlos 
Finlay, who proposed the theory and Major Walter Reed from the United States 
(U.S.) Army who confirmed the theory with well-designed experiments, albeit with 
voluntary human test subjects (4, 5). 
 
We have come a long way since then and the U.S. Centers for Disease Control and 
Prevention (CDC) now lists over 600 identified arboviruses, out of which more 
than 150 are human pathogens. Arbovirus infections when symptomatic, usually 
cause a flu-like illness with fever, headache and nausea. With some viruses, this can 
progress to a severely debilitating rash and arthralgia (chikungunya virus (CHIKV) 
and Ross river virus (RRV)), neurological symptoms like myelitis or encephalitis 
(Venezuelan equine encephalitis virus (VEEV), tick-borne encephalitis virus, West 
Nile virus (WNV)) and hemorrhagic fever (dengue virus, Crimean Congo 
hemorrhagic fever virus, Kyasanur forest disease virus), where thrombocytopenia 
may result in constant bleeding into the tissues, shock and elevated levels of liver 
enzymes (2). Recently, this list of symptoms has been expanded to include Guillain-
Barré syndrome and virus-induced microencephaly in the unborn fetuses and 
newborns of infected pregnant women caused by Zika virus (ZIKV) (6).  
 
Except one DNA virus causing African swine fever, all other arboviruses belong to 
different RNA virus families viz. Flaviviridae, Togaviridae, Bunyaviridae and 
Reoviridae, which have a highly mutable genome and utilize diverse replication 
strategies, allowing these viruses to circulate and effectively multiply in various 
vertebrate and invertebrate hosts. Arbovirus epidemiology is in a state of constant 
flux due to several environmental factors. An ever burgeoning world population, 
urbanization, globalization, expanding air travel and climate change have ensured 
that vector mosquitoes continue to expand their habitats, thereby introducing 
viruses like dengue, chikungunya and Zika into new geographical areas (7).  
 
DENV, a flavivirus primarily spread by Aedes aegypti mosquitoes has by far the 
highest disease burden among the arboviruses. It comprises four circulating 
serotypes, and is endemic throughout the world in the tropical belt. Yearly, there 
are approximately 50-100 million infections of dengue fever, with 10,000 – 15000 
deaths due to severe complications caused by dengue hemorrhagic fever and 
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dengue shock syndrome (2, 3, 7). Recently, another flavivirus spread by the same 
vector mosquitoes - ZIKV, has also emerged as a dangerous arboviral threat, 
presenting new clinical manifestations and also the ability to be sexually 
transmitted (6). CHIKV, an alphavirus that causes severe and persistent arthralgia 
was recently introduced to the New World and has wreaked havoc in Central and 
South America by causing more than 1.5 million infections since the beginning of 
2014 (8). These are just few of the examples of the major arboviral diseases 
plaguing the global population. Several others arboviruses like West Nile virus, 
Japanese encephalitis virus (JEV), Crimean-Congo hemorrhagic fever virus and Rift 
valley fever virus can cause sporadic, life threatening outbreaks, calling for 
improved surveillance, vector control and development of vaccines and antiviral 
therapeutics. 
 
So far, vaccines exist only for yellow fever, Japanese encephalitis and tick-borne 
encephalitis. Recently, Sanofi Pasteur launched Dengvaxia®, a tetravalent vaccine 
against all four circulating serotypes of dengue that has shown good efficacy in 
clinical trials (9). The vaccine has been approved in five countries, with the World 
Health Organization recently recommending that other countries affected with 
dengue should consider employing the vaccine in areas with high endemicity 
(http://outbreaknewstoday.com/costa-rica-approves-dengue vaccine-dengvaxia-
5th-country-to-approve-67888/). Other than these, no antiviral therapies exist for 
any arbovirus and current treatment only involves symptomatic management. 
 
 
 
Figure 1. Arbovirus vectors. (A) Aedes aegypti mosquito which spreads dengue, yellow fever, 
Zika and chikungunya viruses (photo credit: James Gathany, CDC). (B) Aedes albopictus 
mosquito which is competent to spread the same viruses as Aedes aegypti (photo credit: Susan 
Ellis, Bugwood.org). (C) Culex pipiens mosquito which spreads West Nile, Japanese encephalitis 
and Usutu viruses (photo credit: EU 7TH Framework Vectorie Consortium). (D) Ixodes 
scapularis tick which transmits tick-borne encephalitis virus (photo credit: M. Plonsky). (E) 
Phlebotomus papatasi sandfly which transmits several different viral serotypes that cause 
phlebotomus fever (photo credit: Frank Colins, CDC). (F) Culicoides imicola midge which 
spreads bluetongue virus to sheep and cattle (photo credit: French Agricultural Research 
Centre for International Development). 
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2. LITERATURE REVIEW 
 
2.1 Alphaviruses 
 
The Alphavirus genus is contained in the Togaviridae (toga is the Latin word for 
‘cloak’ or ‘shroud’ and refers to the viral envelope) family (10). Alphaviruses (so 
called because they were the first viruses to be classified under Group A 
arboviruses) are positive-sense single-stranded RNA viruses that are all 
arthropod-borne with the exception of salmon pancreatic disease virus and 
Southern elephant seal virus. The genus comprises 29 different virus species 
grouped into 10 antigenic complexes. They are also classified as Old World and 
New World alphaviruses, depending on the geographical location where they were 
discovered and where they are currently distributed (11, 12). 
 
Old World alphaviruses which include Semliki forest virus (SFV), Sindbis virus 
(SINV), O’nyong nyong virus (ONNV), CHIKV and RRV cause a febrile illness 
associated with a maculopapular rash, myalgia and arthralgia, which can often be 
painful and chronic and lead to considerable economic loss and suffering. New 
World alphaviruses on the other hand cause encephalitic disease associated with 
different neurological complications like ataxia, mental depression and aseptic 
meningitis, with VEEV, Eastern and Western equine encephalitis viruses being 
some of the examples (11, 12). In particular, VEEV is important for biothreat 
preparedness due to its ability to be weaponized and spread in aerosol form (13). 
Alphaviruses have been used as tools to study enveloped viruses and additionally 
as vectors for gene therapy (14). 
 
2.2 Alphavirus life cycle 
 
The alphavirus particle is 70 nm in diameter and is made up of a nucleocapsid core 
surrounded by a lipid bilayer derived from the host cell membrane. The viral 
envelope glycoproteins E1 and E2 are embedded in this lipid layer as 80 trimeric 
spikes, with each constituent monomer made up of E1-E2 heterodimers (240 
copies of each protein) arranged in a T = 4 icosahedral lattice. The viral core is 
made up of 240 copies of the capsid protein and this one-to-one relationship 
between the capsid and envelope glycoproteins has been shown to be essential for 
virus assembly. Inside the viral core is packaged the ~11.5kb long viral genome, 
which is a single-stranded positive sense RNA (11, 12). 
 
2.2.1 Receptor attachment and entry 
 
Alphaviruses have a broad host range and cellular tropism, owing to their ability of 
adapt to multiple host requirements, most probably by being able to bind to 
several different types of cellular receptors. Virus attachment is brought about by 
the E2 glycoprotein. Numerous receptor molecules have been implicated – class I 
major histocompatibility protein, heparan sulfate, DC-SIGN, L-SIGN, ?1?1 integrin, 
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glycosaminoglycans, prohibitin etc., and are usually cell-type and species-specific. 
It has been noticed that infection can proceed even in the absence of some of these 
cellular receptors and it is therefore thought that they only aid in the attachment 
process and are not an absolute requirement [reviewed in (15, 16)]. Additionally, 
various residues in the E2 glycoprotein have also been implicated in cell tropism, 
penetration, immunogenicity and pathogenicity of different alphaviruses (17-20). 
Following attachment, internalization is mediated by clathrin-coated endocytosis 
which delivers the viral particle into early endosomes. VEEV, though, has been 
reported to be internalized into late endosomes (21). The mildly acidic pH of the 
early endosome triggers drastic conformational changes in the envelope 
glycoproteins. Initially, E1-E2 heterodimers dissociate, and in this process which is 
regulated by a conserved histidine E2-H170, one of the E2 domains moves away to 
expose the fusion loop of the E1 membrane fusion protein (22). E1 then extends 
and inserts the fusion loop into the target membrane in a cholesterol and pH 
dependent process [reviewed in (15, 16)]. It was shown that a specific mutation in 
E1-226 from alanine to valine made some CHIKV strains have an increased 
cholesterol and lower pH requirement for fusion (23, 24). Further reduction in the 
pH then leads to a complete dissociation of E1 and E2 and leads to E1 trimerization 
– initially a core trimer between Domains I and II of E1 and later an E1 homotrimer 
when Domain III folds back towards the core trimer [reviewed in (15, 16)]. 
Another conserved histidine (H3 in E1) in SFV is essential for the trimerization 
process (25). The opposing membranes are pulled together as a result and the 
outer membrane leaflets merge to form a hemifusion state. Eventually, the 
formation of a fusion pore and its expansion allows the nucleocapsid to enter the 
cytoplasm [reviewed in (15, 16)]. 
 
 
2.2.2 Genome replication and functions of non-structural proteins 
 
Once the capsid enters the cytoplasm, it is disassembled in association with 
ribosomes and translation of genomic RNA proceeds concomitantly (26). The 
alphavirus genome is a single-stranded RNA (~11.5 – 12kb in length) with plus 
polarity and has a 5? cap structure and a 3? polyadenylic acid [poly (A)] tail. The 
RNA is divided into 2 open-reading frames (ORFs) – the initial two-thirds coding 
for the viral non-structural proteins (nsPs) and the latter one-third coding for the 
structural proteins, with two untranslated regions (UTRs) on either side of the 
genome. 
 
Conserved sequence elements 
The alphavirus genome has certain cis-acting elements that are essential for the 
overall replication process. Some of these elements are conserved between the 
alphaviruses and are called Conserved Sequence Elements (CSEs). 
 
CSE1 
It spans the first 44nt of the 5? UTR and forms a stem loop structure that helps 
initiate minus strand synthesis. On the other hand, this region also serves as the 
promoter for plus strand synthesis using the minus strand as a template (27). 
Additionally, this stem-loop structure was found to prevent the recognition of the 
alphaviral 5? cap structure by cellular IFIT1 (Interferon-induced protein with 
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tetratricopeptide repeats), thereby blocking activation of the innate immune 
system leading to enhanced virus replication (28). 
 
CSE2 
This region is 51 nt long and is situated in the initial part of the nsP1 coding 
sequence. This element forms two stem-loop structures (29) that are needed for 
both minus and plus strand RNA synthesis (27). CSE2 was more critical for 
replication in insect cells as compared to vertebrate cells (30). Recently, using the 
SFV trans-replication system it was shown that CSE2 can compensate to some 
extent for the absence of CSE1, inducing some level of minus strand synthesis, 
although the precise mechanism remains to be elucidated (31). 
 
CSE3 
This element is the minimal promoter (24 nt) for the initiation of subgenomic RNA 
synthesis. The full length subgenomic promoter overlaps with the sequence coding 
for nsP4 and continues into the junction region (short sequence between the two 
open reading frames coding for the non-structural and structural proteins) for 
some alphaviruses (32). In alphavirus vector based gene expression systems, a 
duplicated subgenomic promoter is often used to efficiently express the desired 
gene to high levels (33). 
 
CSE4 
CSE4 is a short stretch of nucleotides (19 -24 nt long) immediately before the poly-
A tail in the 3? UTR (34, 35). It forms the core promoter that is needed for initiation 
of minus strand synthesis. Mutations in CSE4 were found to affect minus strand 
synthesis. A minimum length of at least 11-12 poly A residues were needed for 
minus strand synthesis (36). 
 
From the genome, a long polyprotein precursor P1234 is synthesized, which then 
gets cleaved in cis by the autoproteolytic activity of nsP2 into P123 and nsP4 [the 
viral RNA-dependent RNA polymerase (RdRp)] (37, 38). This process differs 
between alphaviruses, where many of them have an opal stop codon at the end of 
nsP3, which is read through to form P1234, with preferential production of P123 
(39). On the other hand, in most isolates of SFV, this opal codon is replaced by an 
arginine residue, resulting in higher production of full length P1234 (40). P123 and 
nsP4 form the early polymerase complex, which is then presumably targeted to the 
plasma membrane to form membrane invaginations called spherules which is the 
active viral replication complex. The recruitment of the viral replicase and genome 
to the plasma membrane to form spherules is still an enigmatic process that 
probably needs the concerted effort of hitherto unknown host factors and specific 
conformational changes and stoichiometric arrangement of the nsPs. The cleavage 
of nsP4 and the membrane-binding property of nsP1 are absolutely essential for 
the formation of replication complexes (41, 42). Recently, using a SFV trans-
replication system (43) it was shown that the size of these replication complex 
spherules is dependent on the length of the template RNA that is being replicated 
(44). In SFV, these replication complexes are completely internalized in a PI3K 
(phosphatidylinositol-3-kinase)-Akt, actin and microtubule-dependent process 
into cytopathic vacuoles (45). On the other hand, in CHIKV (46) as well as SINV 
(47), the spherules are predominantly present on the plasma membrane. 
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Figure 2. Alphavirus RNA genome organization and polyprotein processing. The genome 
is capped and polyadenylated and functions like cellular mRNA, which is directly translated. 
The replicase ORF (Open Reading Frame) codes for the non-structural (ns) polyprotein 
precursor, whereas the structural protein precursor is translated from the 2nd ORF located on 
the subgenomic RNA, which is transcribed from the minus strand. Both precursors are cleaved 
by viral and cellular proteases into the individual proteins. Nature of the cleavages are 
indicated by triangles of different colors. C – capsid; E – envelope. 
 
P123 and nsP4 initiate minus strand synthesis from a promoter on the 3? UTR 
using the genomic RNA as a template (48). Further proteolytic processing then 
cleaves nsP1, which results in nsP1, P23 and nsP4 and brings about a switch from 
minus strand to plus strand synthesis. Additionally, the subgenomic RNA (2nd ORF) 
is transcribed from an internal promoter on the minus strand. P23 species is short-
lived and is cleaved in trans to form the final late polymerase complex comprising 
the individual nsPs, which continue synthesis of the viral genomic RNA and 
preferentially the subgenomic RNA in larger amounts [reviewed in (49, 50)] (Fig. 
2). 
 
Before describing the subsequent processes of the alphavirus replication cycle, a 
brief overview of the individual non-structural proteins is given to describe their 
functions in the replication process. 
 
nsP1 
nsP1 is the viral capping enzyme and possesses methyltransferase (MTase) and 
guanylyltransferase (GTase) activities at its N-terminal end. The alphavirus RNA 
capping reaction proceeds in a different manner as compared to the capping of 
cellular RNAs. GTP and S-adenosyl methionine (AdoMet) are first bound by nsP1. 
 7 
 
nsP1 then catalyzes a reaction where bound GTP is first hydrolyzed to GMP and 
then methylated at nitrogen 7 using AdoMet as a donor, leading to the formation of 
a covalently bound m7GMP-nsP1 complex. The m7GMP is then transferred to the 5? 
end of the newly synthesized RNA genome via a 5?-5?-linkage (51, 52). Cellular 
capping reactions on the other hand first transfer GMP to the nascent RNA, 
followed by subsequent methylation (53). Conserved residues H38 and D64 have 
been shown to be responsible for m7GMP and AdoMet binding respectively and 
bioinformatics analyzes also revealed homologous MTase and GTase domains in 
other plus-strand RNA viruses of the Nodaviridae family (52, 54). Interestingly, the 
presence of uncapped viral genomes was recently observed during SINV and RRV 
infection, which was shown to be responsible for induction of Type I interferon 
(IFN) response (55). 
 
nsP1 is thought to be responsible for targeting the replication complex to the 
membrane due to the presence of an amphipathic membrane-binding peptide in 
the central region of nsP1. This binding is strengthened by the palmitoylation of 
three cysteine residues at the C-terminus (56, 57). Membrane association was 
reported to be critical for SFV replication and the W259 residue in nsP1 was 
shown to be crucial for this property (42). The enzymatic activity of purified SFV 
nsP1 requires membrane association (41), but this was not the case with SINV 
nsP1 (58). The membrane association property of nsP1 induces filopodia-like 
membrane and cytoskeletal rearrangements in infected cells (59), which probably 
have a role in cell-to-cell virus transmission (60). Recently, Jones and co-workers 
showed that CHIKV nsP1 counteracted the tethering restriction effect of a cellular 
interferon-stimulated gene BST2 (bone marrow stromal antigen 2) (61). 
Additionally, second site suppressor mutations have been observed in nsP1 for 
nsP4 mutants defective in minus strand synthesis, suggesting a physical interaction 
between them within the replication complex [reviewed in (50)]. 
 
nsP2 
nsP2 has multiple functions in the infectious life cycle of alphaviruses. The N-
terminal end contains a helicase domain, which also possesses NTPase (nucleotide 
triphosphatase) and RTPase (RNA triphosphatase) activities (62-64). Helicase 
activity unwinds dsRNA during replication and requires NTPase activity (63, 65, 
66). Mutation of a critical residue K192 completely abolished all three enzyme 
activities (63, 66). K192 was shown to be absolutely essential for both RNA 
synthesis and replication complex formation (67). RTPase activity aids in the RNA 
capping reaction by cleaving the terminal phosphate bond at the 5? end of the 
nascent genomic RNA, before transfer of m7GMP cap (64). CHIKV nsP2 was shown 
to possess RNA helicase unwinding activity in the 5? - 3? direction as well as RNA 
reannealing activity (65). Das and colleagues also showed that the truncated N-
terminal domain of purified CHIKV nsP2 alone was not sufficient for these RNA 
modulating effects, but needed to interact with the C-terminal part of the protein 
(65). The helicase activity of a G641D CHIKV nsP2 mutant in combination with a 
C483Y mutation in nsP4 was found to provide greater fidelity to the viral 
polymerase and resistance to the misincorporation of nucleotide analogues, 
suggesting an intimate interaction between the viral helicase and polymerase to 
regulate replication fidelity (68). 
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The other important function of nsP2 is its protease activity, which resides at the 
C-terminal end of the protein. The alphavirus nsP2 protease is a papain-like 
cysteine protease, with conserved cysteine and histidine residues forming the 
catalytic diad. This function is critical for virus replication and mutation of the 
catalytic cysteine completely abolishes polyprotein processing (69). Cleavage of 
P1234 at the 3/4 and 1/2 sites occur in cis (38, 70), whereas cleavage of 2/3 site 
must take place in trans (38). As mentioned earlier, the proteolytic cleavage of the 
viral non-structural polyprotein precursor by nsP2 is a highly orchestrated event, 
which regulates the temporal dynamics of the switch from minus strand to plus 
strand synthesis (70). The processing of the final 2/3 site in SFV requires the N-
terminal part of nsP2 as well as the N-terminal part of the nsP3 (macrodomain), 
~165 amino acids downstream of the 2/3 cleavage site (71). The crystal structures 
of VEEV and CHIKV nsP2 protease domains are one of the few alphavirus protein 
structures that have been resolved, which has now made it an attractive target for 
virtual screening of alphavirus protease inhibitors (72-74). 
 
The nsP2 of Old World alphaviruses has a putative nuclear localization signal (NLS) 
in the C-terminal region and is known to be shuttled to the nucleus during virus 
infection (75). The nuclear translocation of nsP2 was shown to be responsible for 
shut off of host cell transcription (76) and translation (77) as well as evasion of 
type I IFN innate immune response (78, 79). nsP2 brought about the degradation 
of the catalytic subunit of cellular RNA polymerase II (76), and also inhibited 
cellular JAK/STAT signaling to inhibit the Type I interferon response (80). P726G 
mutation in SINV (81, 82) and P718G mutations in SFV (83) and CHIKV (84) were 
shown to either abolish or reduce virus infection induced cytotoxicity. The P718G 
mutation in a CHIKV replicon coupled with the selection of a 5 amino acid insertion 
in nsP2 resulted in the generation of a stable CHIKV replicon cell line (85), which 
has now been used for antiviral studies [I and (86, 87)]. 
 
nsP3 
nsP3 remains the most enigmatic of the alphaviral non-structural proteins. 
Although nsP3 is undoubtedly indispensable for virus replication, no enzymatic 
activity that has a role in the viral life cycle has been assigned to it yet. The protein 
is divided into three-distinct domains. The N-terminal macro domain, whose 
crystal structure has been determined for some alphaviruses (88, 89) has binding 
activity to ADP ribose moieties and RNA. It also possesses a weak ADP-ribose-1??-
phosphate-phosphatase activity, although the RNA binding property is thought to 
be its main function (88, 90, 91). This is the only domain which has some level of 
structural conservation and homology with similar domains from other viruses 
(92). Recently, it was shown that viral macrodomains from three different virus 
families (Coronaviridae, Togaviridae and Hepeviridae) could hydrolyse mono-ADP-
ribose from cellular proteins, and this property was hypothesized to be an 
important pathogenicity determinant (93). The C-terminal region of macrodomain 
is also needed for proper presentation and cleavage of the 2/3 site during 
polyprotein processing (71). Mutations in the macro domain of SINV were shown 
to reduce neuropathogenicity (94). 
 
The central domain is a zinc-binding domain [ZBD; also called the Alphavirus 
Unique Domain (AUD)]. The structural determination of the precleavage form of 
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P23 revealed the presence of this domain that can bind to zinc ions. Additionally, it 
was shown to be important for virus infectivity and thought to be important for 
RNA binding and aiding the macro domain during this process (89). Domain 
swapping of elements downstream of the ZBD between CHIKV and SFV caused 
defects in the resultant chimeric viruses, which were rescued to some extent by 
compensatory mutations in the ZBD, suggesting that the ZBD interacts with the C-
terminal Hypervariable Domain (HVD) (46). 
 
The HVD which is a highly disordered region has a variable length of 150-250 
amino acids between the different alphaviruses. It has recently emerged as a key 
player in virus-host interactions. A series of conserved proline residues in this 
region was found to bind to Src-3 homology domain amphiphysin proteins, which 
influence membrane curvature, possibly shaping the positive curvature in the neck 
region of the replication complex spherule. Mutation of a critical arginine residue 
in the SH3 domain binding motif reduced SFV viral RNA synthesis in cell culture 
and pathogenesis in mice (95). 
 
nsP3 is the only alphavirus phosphoprotein and is highly phosphorylated on 
specific serine/threonine residues (96, 97). Recently, it was conclusively proven 
that this phosphorylated region regulated the internalization of the replication 
complex in SFV through activation of the PI3K-Akt-mTOR pathway. CHIKV, on the 
other hand has fewer phosphorylated residues in this region, corresponding to 
replication complexes localizing to the plasma membrane and reduced activation 
of the PI3K-Akt pathway. Moreover, swapping the entire HVD between these 
viruses led to a switch in phenotypes – both in terms of internalization of spherules 
and the activation of the PI3K-Akt pathway (46). 
 
nsP3 that is not localized in the replication complexes is observed in the cytoplasm 
as punctate foci (98). In recent years, researchers from different groups have 
elucidated the role of the Old World alphavirus nsP3 in sequestering cellular Ras-
GAP SH3 domain binding (G3BP) proteins (or the mosquito homolog rasputin) to 
counteract stress granule-mediated antiviral defense (99). On the other hand, 
G3BP was hypothesized to play a proviral role early during CHIKV infection by 
helping the switch between host cell translation and genome amplification (100). 
The HVD has two FGDF motifs that bind to G3BP proteins. Recently, the crystal 
structure of G3BP in complex with the corresponding binding peptide was 
determined. Schulte et al showed that binding of G3BP at both FGDF motifs are 
necessary for efficient SFV and CHIKV replication. G3BP molecules were predicted 
to tether and stabilize replication complex spherules to the membrane (101). Kim 
and co-workers recently showed that similar motifs in the New World VEEV bind 
to proteins of the Fragile X syndrome family, which are different stress-granule 
related proteins similar to G3BP. They also showed that these stress-granule 
proteins play a key role in viral replication complex assembly (102). As more 
research is being done on nsP3-mediated virus host interactions, a complete 
picture of the nsP3 interactome will gradually emerge. 
 
nsP4 
nsP4 possesses the conserved GDD active site which forms the catalytic core of 
viral RNA-dependent RNA polymerases (RdRp) (103). The N-terminal ~100 amino 
acid residues are unique to alphaviruses, while the remaining ~500 residues make 
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up the viral RdRp with its characteristic palm and thumb domains as predicted by 
sequence alignment (104, 105). nsP4 is synthesized at a significantly lower level 
than the other nsPs due to the presence of the opal codon between nsP3 and nsP4. 
The read through efficiency at this codon is only ~20% (106). The nsP4 needed for 
viral RNA synthesis is presumably shielded in the replication complexes. Excess 
nsP4 in the cytoplasm is targeted for proteasomal degradation by the N-end rule 
due to the presence of an aromatic destabilizing Tyr (tyrosine) residue at the N-
terminal end of nsP4 (107). The aromaticity of this N-terminal residue along with 
the R183 residue were shown to be critical for minus strand synthesis and were 
compensated by a suppressor mutation in nsP1 (108-110). Purification of nsP4 has 
proven to be quite challenging due to its poor solubility. nsP4 with a truncated N-
terminal domain exhibits terminal adenylyltransferase activity, independent of the 
other viral nsPs (105). Full length recombinant nsP4 demonstrated minus strand 
RNA synthesis activity in the presence of P123 (104). 
 
2.2.3 Packaging 
 
The structural ORF is also synthesized as a long polyprotein, and initially, the N-
terminal capsid protein gets cleaved off due to its serine protease autoproteolytic 
activity (Fig. 2). There is a translational enhancer present at the 5? end of the 
sequence coding for the capsid protein in SFV and SINV to ensure efficient 
translation of the structural proteins in the infected cell. This enhancer is not a 
common feature in all the alphaviruses and is missing in VEEV and CHIKV (111). 
Viral genomic RNA is preferentially packaged into capsids, due to a packaging 
signal in the non-structural protein coding region. For SINV and the New World 
encephalitic viruses, this signal is located in nsP1, whereas it was found to be in 
nsP2 for SFV and other viruses belonging to the SFV clade, including CHIKV (112). 
 
2.2.4 Egress 
 
The viral glycoprotein heterodimers of pE2 (precursor of E2 containing E3-E2) and 
E1 are transported through the ER and Golgi, where they undergo conformational 
changes and post-translational modifications like glycosylation and palmitoylation. 
The presence of E3 is thought to prevent premature dissociation of E1-E2 in the 
low pH environment of the ER lumen (113). In the Golgi compartment, furin 
cleavage separates E3 from E1-E2, and the E1-E2 heterodimer is then transported 
to the plasma membrane. This furin cleavage of E3 is essential for subsequent 
fusion and virus entry into newly infected cells (114, 115). E1-E2 heterodimers 
self-assemble into trimeric spikes on the plasma membrane. The assembled and 
filled nucleocapsids are thought to diffuse to the plasma membrane, where one-to-
one interaction between a hydrophobic pocket on the capsid protein and E2 tail 
drives the budding process (116, 117) to generate progeny virions [reviewed in 
(14)]. 
 
2.3 Epidemiology of chikungunya virus infections 
 
The rapid spread of chikungunya fever across the globe has recently put the 
spotlight onto the alphaviruses. Although other alphaviruses like VEEV and SINV 
 11 
 
are important human pathogens, neither of them have garnered so much research 
and media attention. In fact, with the re-emergence of CHIKV, alphavirologists have 
been able to use their existing knowledge and expertise to help dissect the finer 
details of this geographically expanding disease. 
 
Chikungunya fever leads to a febrile illness that is characterized by nausea, 
headache, acute musculo-skeletal pain and a maculopapular rash. Long term 
persistent myalgia and arthralgia can occur in a majority of the affected 
individuals. In rare situations, neurological and ocular defects have been reported 
(8). It is speculated that CHIKV has been in circulation for centuries and was often 
misdiagnosed as dengue fever due to the similarity in clinical symptoms. In fact, 
there have been reports of a ‘knuckle/joint fever’ in Indonesia as far back as in 
1779, which could very well have been an outbreak of CHIKV infection (118). 
Chikungunya has been maintained in an enzootic or sylvatic cycle involving non-
human primate hosts/reservoirs and arboreal vector mosquitoes of the Aedes 
species. Eventually, CHIKV was introduced into the urban epidemic cycle involving 
a man-mosquito-man transmission pattern, being primarily circulated by the 
tropical urban vector Aedes aegypti (119). 
 
CHIKV was first isolated in Tanzania in 1952 and the name of the disease comes 
from the Makonde language roughly translated as ‘that which bends up the joints’ 
(120, 121). Shortly thereafter, CHIKV was detected in several places of East Africa 
and these strains were classified into the ECSA (East/Central/South African) 
lineage. Later in the 20th century, several smaller episodes of CHIKV infection in 
Senegal and related areas were observed. Strains obtained from these outbreaks 
formed the West African lineage. At the same time, sporadic CHIKV cases were 
being detected in different places in Asia. In the period of 1958 – 1973, CHIKV was 
detected in Thailand, Cambodia and India in several different outbreaks, 
sometimes co-circulating with dengue fever. The viruses from these outbreaks 
collectively formed a separate Asian epidemic lineage. The Asian lineage 
disappeared from India after 1973, but maintained its presence in Southeast Asia 
through small scale epidemics [reviewed in (122)]. 
 
For the next 30 odd years, CHIKV faded out of memory until 2004 when a new 
epidemic strain emerged from the ECSA lineage. Initially circulating in coastal 
Kenya, in 2005 it spread to several islands in the Indian ocean like Mauritius, 
Comoros, Mayotte and most notably, the French territory of La Réunion, where 
around one third of the island’s population (~300,000) was infected (123). Genetic 
analysis of this emergent strain now classified as the Indian ocean lineage, along 
with vector competence and vector transmission studies revealed the presence of a 
dominant A226V mutation in the E1 fusion protein (124), which made this strain 
increasingly dependent on cholesterol for membrane fusion and better adapted to 
the less common, secondary vector - Aedes albopictus (24). This epidemic then 
spilled over onto the Indian subcontinent, where in a span of less than 2 years, 
more than 1.5 million infections occurred (125). At the same time, the virus also 
spread to Southeast Asia where millions of individuals in several different 
countries were affected. Moreover, strains from the Asian lineage also saw a 
resurgence with active circulation in Southeast Asia and further spread to Oceania 
[reviewed in (122)]. 
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In subsequent years, the CHIKV epidemic raged on at lower intensities in these 
tropical endemic countries. During this period, there were several reports of 
imported CHIKV infections as a consequence of western tourists visiting areas with 
active CHIKV circulation. Some of these importations led to local CHIKV epidemics 
in Europe – first in Italy in 2007 (126) and later in southern France in 2010 (127), 
where the temperate vector Aedes albopictus had already been established. 
  
Fig. 3 Geographical distribution of chikungunya virus and its vectors. The map indicates 
the important outbreaks since the virus was first isolated in 1952, with different symbols 
denoting the three genotypes. Color coded areas depict the spread of the two vectors – Aedes 
aegypti and Aedes albopictus. (Photo credit: adapted by J. Hirshfeld, Geoatlas/Graphi-Ogre). 
 
These events highlighted the possibility of CHIKV spreading to new geographical 
locations that were not restricted to tropical areas, as well as the western 
hemisphere, where these vector mosquitoes are already endemic. 
 
This prediction came true not soon after when CHIKV cases were reported in some 
Caribbean islands in late 2013. Surprisingly, the etiologic strain was from the Asian 
lineage, probably imported from Southeast Asia or Oceania (128, 129). Thereafter, 
it rapidly spread across Central and South America as well as northward into 
Mexico and the U.S.A., where local transmission resulted in 11 cases in the 
southern state of Florida (130). Additionally, later in 2014, a strain from the ECSA 
lineage was introduced into Brazil and currently both these strains are circulating 
in the Americas and threaten to become endemic in urban settings as well as being 
established in the enzootic cycle like yellow fever virus (YFV) (131). So far, more 
than 1 million cases have been reported in the western hemisphere, with many 
more probably being misdiagnosed as dengue fever in regions which do not have 
access to diagnostic infrastructure (8). 
 
Disability Adjusted Life Years (DALYs) is often used as an indicator of the 
epidemiological burden of a disease. It measures the number of ‘healthy’ years lost 
due to ill health, disability or early death. For the Indian outbreak of 2006-2007, 
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the DALY was estimated to be ~26,000 (132); whereas for the current epidemic in 
Central and South America the modest lower estimate DALY is > 150,000 (133). 
This fact highlights the explosive nature of this disease and its spread to millions of 
immunologically naïve individuals, leading to widespread economic losses. 
 
Urgent intervention measures are needed to tackle this pathogen. There are 
several different vaccine strategies that have been employed and they seem to 
offer protection in mouse models, non-human primates and have progressed to 
Phase I clinical trials with promising results. Nevertheless, it might take quite a 
while before a vaccine to be used in endemic countries is licensed. Vaccine 
manufacturing scale-up, technical and regulatory details, feasibility for medium 
and large-scale companies to invest in these ventures due to the target population 
largely restricted to low and middle-income countries are all issues that might 
affect the timeline [reviewed in (134, 135)]. In such a scenario, therapeutic 
measures might be a likely recourse. Ever since the re-emergence of CHIKV in 
2004, several groups all over the world have been in the pursuit of screening and 
discovering potential antiviral compounds that inhibit CHIKV. So far, no approved 
antivirals exist and treatment of patients is limited to symptomatic management 
(136). 
2.4 Antivirals and antiviral validation 
 
Antivirals are chemical agents that interfere with a productive viral infection 
without causing adverse toxicity to the host cell (137). The first ever antiviral to be 
licensed was the thymidine analogue, idoxuridine against the herpesviruses which 
interferes with thymidine phosphorylase and the viral DNA polymerase. Its 
synthesis and activity was first described in 1959 (138) and it was formally 
approved in 1963. Since then, over 90 antiviral drugs have been approved for 
human use against a wide variety of pathogenic viruses e.g., different members of 
the Herpesviridae family, human immunodeficiency virus (HIV), influenza virus, 
hepatitis B virus (HBV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) 
and human papilloma virus [reviewed in (139)]. Nevertheless, as compared to the 
rapid advancement of antibiotics from discovery to the clinic, antiviral discovery 
and development has been slow and fraught with many obstacles. Viruses are 
obligate intracellular parasites that hijack different cellular processes to facilitate 
their own replication and as a result, very few inhibitors achieve selectivity against 
a virus-specific process without leading to detrimental effects in the host cell. 
Secondly, incomplete inhibition or lack of adherence to prescribed drug regimen 
can lead to the emergence of resistant populations. Finally, with many emerging 
and exotic viruses [Middle Eastern Respiratory Syndrome coronavirus, Ebola virus 
(EBOV)], the systematic validation of antiviral drugs requires specialized handling 
facilities and equipment, including high containment laboratories (biosafety level 3 
and 4), which are difficult and expensive to maintain. Some viruses are difficult to 
propagate in cell culture (HBV), whereas some others do not have appropriate 
animal models for pre-clinical trials (measles virus) [reviewed in (137)]. 
Therefore, as new pathogenic viruses continue to emerge and other prevalent ones 
develop resistance to existing therapeutic measures, the search for potent and 
effective antivirals must continue. 
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2.4.1 Classes of antivirals 
 
Antivirals can be broadly classified as direct-acting (targeting a viral component) 
and host-directed (targeting one or more host factors required for the viral 
infectious cycle) antivirals (137). Dr. Erik de Clercq from the Rega Institute of  
Medical Research (Leuven, Belgium), who has been a pioneer in antiviral drug 
development for more than 50 years, has recently published a comprehensive 
review of approved antiviral drugs (139), where he has classified antiviral drugs 
into 13 different classes based on their functional chemical groups and mode of 
action which are as follows: 
 
5-substituted 2?-deoxyuridine analogues 
These were the first antiviral drugs to be approved and include idoxuridine, 
trifluridine and brivudine. They act as thymidine analogues and target the viral 
DNA polymerase of HSV-1 (140). Brivudine is also active against Varicella zoster 
virus (VZV) DNA polymerase (141). 
 
Nucleoside analogues 
Vidarabine, entecavir and telbivudine are the approved antiviral nucleoside 
analogues.  Vidarabine triphosphate acts against the DNA polymerase of HSV and 
VZV by competing against dATP (142), whereas both entecavir and telbivudine are 
used especially against HBV infection, where they act by inhibiting the HBV DNA 
polymerase (139). 
 
Pyrophosphate analogues 
Foscarnet is the only approved drug in this class. Its uniqueness lies in the fact that 
unlike nucleoside analogues, it does not need to be phosphorylated before it binds 
to the target viral DNA polymerase (143). Foscarnet has broad spectrum antiviral 
activity against viral DNA polymerases of different DNA viruses like HSV1 and 2, 
human cytomegalovirus (HCMV), VZV, Epstein-Barr virus (EBV) and HBV; but it 
does not show any activity against the RdRps of RNA viruses. Additionally, it is also 
used against HIV (144). 
 
Nucleoside reverse transcriptase inhibitors (NRTIs) 
There are several approved drugs belonging to this class – zidovudine, didanosine, 
zalcitabine, stavudine, lamivudine and abacavir. They compete with cellular 
nucelotides to act as chain terminators for viral DNA synthesis. Most of them have 
been approved and used against HIV, except lamivudine which is also used against 
HBV [reviewed in (139)]. 
 
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) 
Five approved anti-HIV drugs fall in this category – nevirapine, delavirdine, 
efavirenz, etravirine and rilpivirine. These compounds are non-competitive 
allosteric inhibitors of the HIV reverse transcriptase and do not need to be 
metabolically processed (145). They are often used as first-line treatment in the 
clinical setting (146). 
 
Protease inhibitors 
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In this particular class, there are 12 HIV aspartic protease inhibitors viz. 
saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, atazanavir, fosamprenavir, 
lopinavir, tipranavir, darunavir. Most of them are peptidomimetic compounds that 
bind to the active site of the HIV protease and interfere with the processing of its 
proteins. They form an integral part of the HAART (Highly Active Anti-Retroviral 
Therapy) regimen for patients infected with HIV-1 and HIV-2. Recently, directly-
acting antivirals have been approved against HCV which include NS3/4A serine 
protease inhibitors: asunaprevir, boceprevir, paritaprevir, simeprevir, telaprevir, 
vaniprevir and grazoprevir. In some countries like Japan, they have been approved 
in combination with other drugs and PEGylated interferon to treat infections with 
HCV genotype 1. Other HCV protease inhibitor candidates are in clinical 
development [reviewed in (139)]. 
 
Integrase inhibitors 
These are compounds that block the strand-transfer reaction catalyzed by HIV 
integrase to integrate its proviral DNA into the host chromosome (147). Three 
integrase inhibitors - raltegravir, elvitegravir and dolutegravir have been approved 
for clinical use. These compounds are also part of the HAART therapy in 
combination with different NRTIs and protease inhibitors (139). They generally 
have a better safety profile and a higher genetic barrier to the development of 
resistance (148). 
 
Entry inhibitors 
Within this class of antivirals, there are several different types of drugs. Enfuvirtide 
(also known as T-20) is a polypeptide drug that binds to a heptad repeat in the HIV 
envelope protein GP41 and prevents the fusion of the viral and cellular membranes 
(149). Maraviroc is a chemokine receptor antagonist that prevents the binding of 
HIV with one of its essential co-receptors CCR5 on the surface of CD4+ T cells and 
macrophages (150). RSV-IGIV and palivizumab are immunoglobulins that were 
approved for prophylactic use against RSV. RSV-IGIV may prevent binding of F & G 
glycoproteins of RSV to host cells, whereas palivizumab binds to a specific 
conserved residue on the RSV fusion protein and offered neutralization as well as 
inhibition of fusion (151). VZIG and VariZIG are immunoglobulins against VZV used 
prophylactically as well as for post-exposure prophylaxis to reduce clinical illness 
in immunocompromised patients (152). Docosanol is a saturated primary alcohol 
that is used in topical creams against HSV and supposedly prevents virus entry by 
blocking attachment of HSV envelope proteins to cell membrane receptors (153, 
154).  
 
Acyclic guanosine analogues 
Acyclovir, ganciclovir, penciclovir and their phosphorylated prodrugs are used to 
treat both HSV and VZV. Once they are in their triphosphorylated forms, they 
compete with the cellular dGTP substrate of viral DNA polymerase to inhibit DNA 
synthesis [reviewed in (139)]. 
 
Acyclic nucleoside phosphonate analogues (ANPs) 
Cidofovir, adefovir dipvoxil, tenofovir disproxil fumarate (TDF) are compounds 
belong to this class of drugs. Cidofovir is primarily used to treat HCMV, adefovir 
and TDF are used in combination therapy to treat HIV and HBV. ANPs are effective 
chain terminators of DNA synthesis, because of the presence of their phosphonate 
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linkage, which cannot be cleaved by cellular hydrolase esterases [reviewed in 
(155)]. 
 
HCV NS5A inhibitors 
Direct-acting antivirals against HCV are recent entrants in the market. So far, four 
of them have been approved – daclatasvir, ledipasvir, ombitasvir and elbasvir. 
These compounds bind specifically to HCV NS5A and were shown to block 
replication by disrupting the formation of the membranous web that is found in 
HCV replication complexes (156).  
 
HCV NS5B polymerase inhibitors 
Two drugs, sofosbuvir and dasabuvir have been approved. These compounds 
target the allosteric site of the HCV NS5B polymerase. They are used in 
combination with other drugs for effectively treating HCV [reviewed in (139)]. 
 
Influenza virus inhibitors 
Amantadine and rimantadine are both influenza virus M2 ion channel protein 
blockers which prevent proton translocation into the endosomes, thereby 
preventing the uncoating of the virus particle (157). Zanimivir, the relatively more 
successful oseltamivir and other derivatives like peramivir and laninamivir 
octanoate are the results of a rational computer-based design against IAV 
neuraminidase (158). These compounds prevent viral release from infected cells 
by binding to neuraminidase and preventing the cleavage of sialic acid residues on 
the viral hemagglutinin protein (159). Ribavirin is a broad-spectrum antiviral drug 
that is approved for treatment of IAV infections, but also works against many other 
RNA viruses like HCV, RSV, DENV etc. (160). This compound blocks the de novo 
synthesis of GTP by inhibiting the inosine-5? monophosphate (IMP) dehydrogenase 
enzyme (161), thereby inhibiting the activity of the IAV RNA polymerase (162). 
Another compound favipiravir which has been approved to treat IAV in Japan gets 
converted intracellularly to its active triphosphate metabolite (163) and shows 
broad-spectrum activity against many positive and negative-sense RNA viruses 
(164). 
 
Antiviral agents not directed against viral proteins 
Interferon (pegylated interferon alpha 2b) therapy, which triggers innate immune 
antiviral defenses has been approved for treating HBV and HCV infections in 
combination with ribavirin, although its use is not widespread in clinical practice 
[reviewed in (139)]. Imiquimod is a cytokine stimulant and it is approved as a 
topical cream for treating HPV-induced genital warts (165). Sinecatechins is a 
plant-derived immunomodulatory product used as a topical ointment for treating 
HPV-induced warts (166). Podofilox is an antimitotic compound approved as a 
topical solution or gel to treat external warts. It works by disrupting mitotic 
spindle formation during the metaphase stage (167). Fomivirsen is an antisense 
oligonucleotide targeting the expression of an immediate early gene during HCMV 
infection (168). It was approved as an intravitreal injection into human eyes to 
treat HCMV retinitis in AIDS (Acquired Immunodeficiency Syndrome) patients 
[reviewed in (139)]. 
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This brief overview of approved antiviral drugs highlights the fact that antiviral 
drug research has primarily focused on diseases that are prevalent in the western 
world and quite often diseases endemic in the tropical areas and in third-world 
developing countries have been neglected. 
     
2.4.2 Antiviral drug discovery 
 
The process of a systematic antiviral drug discovery program entails the following 
steps: 
 
1. Target identification 
This process involves finding a potential drug target in the viral life cycle, which 
can either be a virus-encoded protein or host factors that are needed for efficient 
virus replication. 
 
2. Target validation 
Targets that are indispensable for virus replication need to be identified and 
validated, wherein targeting them leads to reduced virus replication in cell culture 
or confers a therapeutic effect in an animal model. 
 
3. Lead identification 
Following validation of a target, assays need to be developed and optimized, 
wherein the biological function mediated by the target can be accurately assessed. 
This is usually followed by a screening process where compounds depicting dose-
dependent activity and selectivity against the target, within predefined cytotoxicity 
thresholds are selected for further optimization. 
 
4. Lead optimization 
In this process, the lead compound or molecule undergoes further refinement, 
possibly in terms of structural modifications to enhance its potency and selectivity 
towards the target. 
 
Once the candidate drug clears this initial phase of testing and optimization, it 
needs to undergo rigorous pre-clinical evaluation in animal models to ascertain its 
effectiveness and also to obtain pharmacokinetic and toxicity profiles. The next 
step is clinical trials in human volunteer test subjects that are classified into four 
phases, with approval granted if the drug clears the first three phases [reviewed in 
(137, 169)]. 
 
2.1.1 Antiviral screening 
 
Screening for inhibitors is an integral process of the drug discovery program, 
which contributes significantly to the generation of new lead candidates. This 
becomes especially important when the pathogen in question is an exotic or re-
emerging virus, where both the life cycle and the processes involved, or the 
structures of the different virus-encoded proteins are unknown. In such cases, 
infection assays are often used to screen for inhibitors interfering with different 
stages of the viral life cycle. There are different readouts that are employed in 
these infection assays, such as CPE (cytopathic effect) reduction (170), viral 
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protein expression determined by immunofluorescence (171), high throughput dot 
blot assays (172), FRET-based viral protease activity readout (173) etc. Often, a 
reporter gene cloned into the viral genome is used as a readout of a productive 
infection and its reduction as a measure of antiviral activity of the compounds 
being screened (174). In case of viruses which have a higher biosafety 
requirement, often non-pathogenic, but related surrogate viruses (175), 
pseudotyped viruses (non-pathogenic viruses expressing only the envelope 
proteins of the virus under study) (176, 177), viral replicons (178) or cell lines 
stabling expressing replicons are used (85, 179). Indirect approaches using cell-cell 
fusion assays and measuring resultant syncytia formation in infected cells (180) or 
measuring cellular electrical impedance (181) are innovative methods to screen 
for viral fusion inhibitors. Another approach is to use recombinant purified active 
viral enzymes in cell-free enzyme substrate assays (182, 183). High-resolution 
crystal structures of viral enzymes offer an additional advantage for the screening 
process. Computational methods for structure or ligand-based virtual screening of 
millions of compounds helps to narrow the list of potential inhibitors to those that 
presumably bind with highest affinity (184). This approach is often constrained by 
predefined thresholds based on the programs and software being used for this 
purpose (137). The hits generated from such in silico approaches are then 
validated either with in vitro enzyme substrate assays or isothermal titration 
calorimetry binding affinity assays and infection assays using live virus (185).  
 
So far, we have concentrated on screening for inhibitors that interfere with viral 
processes. In a complementary approach, host factors that are critical or essential 
for the viral life cycle are also screened. Since the discovery of RNAi (RNA 
interference) a decade ago, knockout of specific cellular processes via siRNA to 
identify crucial proteins or pathways in the viral life cycle has been a widespread 
approach (186). These screens are often unbiased genome-wide screens (187) or 
involve selectively knocking out only specific types of proteins like kinases (188). 
In recent years, with the advent of the CRISPR-Cas9 gene editing tool, it has been 
possible to achieve high efficiency in knockdown, few off target effects and less 
signal/noise ratio, thereby increasing the effectiveness of such screens (189). Yet 
another exciting recent development is the use of haploid human cells for 
screening host factors (190), where knockout of a particular gene results in 
complete loss of function, due to only one copy of the particular gene being present 
(191). Some studies have even combined the use of these powerful tools to reveal 
novel host factors regulating viral infection (192). Some of these host factors can 
be targets for other diseases like diabetes and cancer and there is a good chance 
that FDA (Food and Drug Administration)-approved drugs that target these factors 
are available. These existing medications can then be repurposed for antiviral use 
(193). Inversely, using libraries of FDA-approved drugs in viral screening setups 
could also yield similar results. 
  
 19 
 
 
2.4.3 Antivirals against chikungunya virus 
 
Potential drug targets in the alphavirus life cycle are represented in Fig. 4 and 
select inhibitors against these targets are listed in Table 1. There are several other 
inhibitors with unknown targets that have been reported to possess antiviral 
activity against CHIKV. The reader is referred to comprehensive reviews on 
antivirals against CHIKV by Abdelnabi et al (2015) and Kaur and Chu (2013) for 
further details. 
 
 
 
Figure 4. CHIKV life cycle and potential drug targets. Schematic representation of the 
major steps/druggable targets in the CHIKV infectious cycle. 1 – receptor-binding and clathrin 
coated endocytosis, 2 – membrane fusion, 3 – capsid disassembly, 4 – polyprotein translation, 5 
– non-structural protein enzymatic activity, 6 – RNA replication, 7 – subgenomic RNA 
translation, 8 – capsid protein cleavage, 9 – genome packaging, 10 – signalase cleavage in the 
ER, 11 – furin cleavage of the E3 protein and 12 – budding. [Adapted from (136)]. 
 
  
 20 
 
 
Table 1. Potential drug targets in the CHIKV life cycle and their inhibitors 
No. Target Inhibitor Reference 
1 
Receptor-binding and 
clathrin-coated 
endocytosis 
Arbidol (197, 198) 
  
Compounds with a 10H-
phenothiazine core 
(85) 
  Flavaglines (199) 
  
Epigallocatechin gallate (green 
tea component) 
(200) 
  Suramin (201, 202) 
2 Membrane fusion Chloroquine (203, 204) 
3 Capsid disassembly - - 
4 
Translation of viral 
genome 
Phosphorodiamidate 
morpholino oligomers 
(205, 206) 
  siRNAs against nsP3 and E1 (207) 
  siRNAs against nsP1 and E2 (208) 
  shRNAs against nsP1 and E1 (209) 
5 
Enzymatic activity 
a) nsP1 capping activity 
[1,2,3]triazolo[4,5-
d]pyrimidin-7(6H)-ones (210) 
 b) nsP2 helicase - - 
 c) nsP2 protease 
ID1452-2 
 
(211) 
 
  Compound 1 (73) 
  
Arylalkylidene derivative of 
1,3-thiazolidin-4-one 
(212) 
  
NCI_217697, NCI_61610, 
NCI_37553 and NCI_293778 
(74) 
  Compounds 3a, 4b and 5d (213) 
 d) nsP3 macrodomain 
NCI_61610, NCI_25457, 
NCI_345647_a, NCI_670283, 
NCI_127133 
(214) 
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 e) nsP4 polymerase - - 
6 
Viral genome 
replication 
Ribavirin (215, 216) 
  Mycophenolic acid (217) 
  6-azauridine (215) 
  Favipiravir (T-705) (196) 
7 
Translation of 
subgenomic RNA 
Hammerhead ribozymes (218) 
8 
Capsid protein serine 
protease activity 
- - 
9 Viral genome packaging - - 
10 
Signalase cleavage in 
the ER 
- - 
11 
Furin cleavage of E3 
protein 
Decanoyl-RVKR-chloromethyl-
ketone 
(219) 
12 Budding - - 
13 
Targeting host factors 
a) Protein kinase C 
activators 
Tigliane diterpenoids 
prostratin and 12-O-
tetradecanoylphorbol 13-
acetate 
(220) 
  Bryostatin analogues (221) 
 b) Kinase inhibitors 
Compounds with a benzofuran 
core scaffold, pyrrolopyridine 
scaffold and a thiazol-
carboxamide scaffold 
(222) 
 c) HSP90 inhibitors HS-10 and SNX-2112 (223) 
 d) Fatty acid synthesis 
5-tetradecyloxy-2-furoic acid 
and orlistat 
(224) 
 e) Calmodulin signaling 
TAE684, pimozide and 
perphenazine 
(224) 
 
f) Sodium-potassium 
ATPase 
Digoxin and ouabain (225) 
 
g) Polyamine 
biosynthesis 
Difluoromethylornithine and 
diethlynorspermine 
(226) 
14 
Modulating host 
immune response IFN-? (215) 
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TL3 agonist polyinosinic 
acid:polycytidylic acid 
(227) 
  
RIG-I (retinoic acid-inducible 
gene – I) agonist 5? 
triphosphorylated RNA 
molecule 
(228) 
  
Monocyte chemoattractant 
protein-1 inhibitor bindarit 
(229) 
  
STING agonist G-10 and 5,6-
dimethylxanthenone-4-acetic 
acid 
(230) 
 
 
 
There are few inhibitors which have been validated in a mouse model of CHIKV 
infection, which deserve more attention: 
 
Favipiravir 
Favipiravir (also known as T-705 or Avigan) is a pyrazinecarboxamide derivative 
that has been licensed in Japan for treating IAV infections.  It was also shown to 
possess broad-spectrum antiviral activity against several different RNA viruses 
from various families (194). Favipiravir is a prodrug that gets converted to its 
active metabolite - ribofuranosyl-5?-triphosphate by the cellular HGPRT 
(hypoxanthine guanine phosphoribosyltransferase) enzyme and competitively 
inhibits the activity of the viral RdRp in a GTP-dependent manner (163). Two 
possible modes of action have been proposed, although they remain to be 
conclusively proven: a) it works as a chain terminator and prevents elongation of 
the nascent RNA molecule, b) it induces lethal RNA transversion mutations that 
eventually results in error catastrophe and a non-viable virus (195). However, 
unlike ribavirin (another broad-spectrum antiviral), favipiravir is not active 
against DNA viruses (194). Delang and co-workers described the antiviral effect of 
favipiravir against CHIKV. Favipiravir offered protection in a lethal mouse model of 
CHIKV-induced neurological disease, where disease severity was reduced and 
mortality was reduced by more than 50%. Furthermore, mutation K291R 
(conserved residue in the polymerase of all plus-strand RNA viruses) in the viral 
RdRp was shown to confer low level phenotypic resistance against favipiravir 
(196). 
 
Bindarit 
Bindarit is a small-molecule indazolic compound possessing anti-inflammatory 
properties and predominantly targeting the expression of CCL2 [also known as 
monocyte chemoattractant protein (MCP) 1] and other proinflammatory cytokines 
like CCL8, CCL7 and IL (interleukin)-12 (231). Bindarit was also reported to be 
active against other disorders like breast cancer (232), adjuvant-induced arthritis 
(233), lupus nephritis (234) etc. Chen et al had reported earlier that alphavirus 
infection could trigger loss in bone volume in the tibial epiphysis in an 
immunocompetent C57BL/6 mouse model and induce the production of 
proinflammatory cytokines in infected bone osteoblasts (235). Bindarit was shown 
to prevent the bone damage mediated by CCL2 induced osteoclastogenesis and 
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bone resorption (229). This study also highlighted the potential of similar anti-
inflammatory drugs used against rheumatoid arthritis being repurposed against 
CHIKV-induced chronic arthralgia. 
 
HSP-90 inhibitors 
Heat shock proteins (HSP) are chaperone proteins that aid in protein folding and 
regulate multiple functions in the cellular environment (236). HSP-90 was shown 
to interact with CHIKV nsP3 and nsP4 and siRNA knockdown of HSP90 reduced 
CHIKV replication. Two synthetic inhibitors of HSP90, HS-10 and SNX-2112 
reduced viral RNA and protein expression. The same study also showed that these 
compounds reduced viral load in infected SvA129 mice (deficient in Type I IFN) 
and that treated mice did not show any CHIKV-induced inflammation or swelling 
(223). 
 
RNA interference strategies 
Different groups have tried the RNA interference approach to inhibit CHIKV 
replication in vitro and in vivo. siRNAs targeting the CHIKV nsp1 and E2 regions or 
a combination of both led to a significant reduction in CHIKV RNA expression in 
vitro. More importantly, siRNA treatment at 72 h p.i. significantly reduced viral 
loads in serum and muscle tissues of Swiss albino and C57BL/6 mice (208). In a 
similar approach, plasmid based shRNAs (short hairpin RNAs) against the viral 
nsP1 and E1 genes resulted in significant reduction in virus particle production in 
HeLa cells. Pretreatment of suckling C57BL/6 mice with 60 μg of shRNA E1 
resulted in complete survival of the infected mice even after 10 days p.i (209). The 
same group used yet another approach to target the viral RNA, using 
phosphorodiamidate morpholino oligomers which are single-stranded 
oligonucleotides with six-membered morpholine rings and nucleotide bases linked 
by a phosphorodiamidate bond. These antisense nucleotides can bind to their 
complementary RNA sequence with high affinity and thereby create a physical 
steric hindrance for ribosome assembly on the target RNA molecule and prevent 
subsequent RNA translation. Pretreatment of HeLa cells with these antisense 
oligomers significantly decreased viral titer and protein expression. Moreover, 6-
day old BALB/c neonate mice were completely protected on treatment with 15 
μg/g of the phosphorodiamidate oligomer treatment given twice before infection 
and two more doses post-infection (205). 
 
STING agonist 
Recently, a novel approach of triggering the innate immune system against CHIKV 
infection has been successful. In a high throughput screen for molecules having the 
ability to activate the IRF (Interferon Regulatory Factor) 3/IFN-dependent innate 
immune responses, the compound termed as G-10 was identified which was able 
to dose-dependently reduce replication of CHIKV, VEEV and SINV in human cells. 
Using gene editing tools, the compound was determined to be a STING (Stimulator 
of IFN genes) agonist. Another unrelated small molecule STING activator called 
DMXAA (5,6-dimethylxanthenone-4-acetic acid) that works only in mice was found 
to reduce CHIKV viral load in 5-7 week old C57BL/6J mice when administered 3 h 
prior to infection and 6 h p.i. However, the reduction in viremia was not significant 
when the compound was given 24 h p.i. (230). 
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2.4.4 Mouse infection models for chikungunya virus 
 
Animal models are required to investigate the pathophysiology of any disease. 
With regard to viral infections, having an animal model that replicates the disease 
symptoms and progression in humans is extremely important in order to evaluate 
the efficacy of vaccines as well as antiviral therapies. As early as in 1956, Ross 
discovered that intracerebral inoculation of neonate Swiss albino mice (< 12 days 
old) with sera from acute-phase CHIKV patients led to 100% mortality (121). It 
was only after the large-scale epidemics in 2005-2006 that there was renewed 
interest in CHIKV and the need to develop appropriate animal models. Adult 
immunocompetent mice are not susceptible to CHIKV-induced disease due to 
protection conferred by a robust IFN response whereas neonate mice show 
lethality following intradermal inoculation (237, 238). Couderc et al developed 
IFN-?/? receptor knockout (IFN-?/?R –/–) adult mice which were permissive to 
CHIKV infection and developed severe disease and mortality 3 d p.i. Interestingly, a 
partial abrogation of the IFN-?/? receptors (IFN-?/?R +/–) did not result in any 
disease signs, but viral presence was detected in the muscles and joints (238). At 
the same time, Ziegler and co-workers used sub-cutaneous inoculation of CHIKV in 
two strains (ICR and CD-1) of outbred newborn and neonate mice and observed 
arthritogenic disease manifestations of acute CHIKV disease including difficulty in 
walking, imbalance and severely reduced hind limb movement, but reduced the 
mortality that was observed earlier in mice from this age group (239). 2-3 day old 
mice when inoculated with CHIKV sub-cutaneously developed hind limb paralysis 
and diseased tissues were used for proteomic analysis to screen for host factors 
that may contribute to myositis (240).  
 
Although these infection models provided valuable information on different 
aspects of CHIKV tissue tropism and the control exerted by the innate immune 
response in limiting in vivo disease, they could not recapitulate the muscle and 
joint pathology normally associated with CHIKV disease in humans [reviewed in 
(241)]. Secondly, the use of immune deficient or immunologically immature mice 
might not accurately portray the immunopathogenesis of CHIKV. Besides, in 
humans CHIKV infection rarely results in fatal disease, but instead depicts 
symptoms associated with chronic myalgia and polyarthralgia in distal joints. As a 
result, several groups began to develop mouse models which sought to mimic the 
arthralgic and myalgic complications associated with CHIKV disease – with juvenile 
mice (14 – 21 day old) (242) and also with adult immunologically mature mice (6 
week old) (243). Instead of the more traditional routes of inoculation in mice, the 
site of infection was moved to the ventral side of the hind limb at the footpad, 
towards the ankle. As a result, this model was able to mirror the self-limiting 
arthritis, tenosynovitis and myositis that is associated with CHIKV disease in 
human patients (242, 243). Acute disease phase symptoms included peak foot 
swelling 6-8 days p.i., viremia was observed for 4-5 days and viral presence in the 
foot peaked 24 h p.i., with infectious viruses being detected in the feet up to 9 days 
p.i (243). Histological analyzes of feet from infected mice showed tell-tale signs of 
severe damage, with huge amount of mononuclear cell infiltrates around the 
synovial membranes, swelling, inflammatory cell infiltration near the tendons and 
extensive necrosis of the muscle fibers [reviewed in (241)]. Several different 
mutant models derived from the footpad model have been used in studies to 
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delineate the role of the innate immune response in CHIKV pathogenesis. Despite 
these advancements, there is still no mouse model that can replicate the chronic 
arthralgia that is observed in 30% of infected humans [reviewed in (244)]. Adult 
Cynomolgus macaques is a non-human primate model for CHIKV disease that can 
successfully recapitulate the chronic manifestations of CHIKV fever. However, they 
are not feasible to work with due to ethical issues and high maintenance costs 
(245). Humanized mouse models which have gained popularity with other 
diseases might be one way to go forward (244). 
 
2.5 MAP kinase signaling in the context of viral infections 
 
The mitogen-activated protein kinases (MAPKs) together constitute a repertoire of 
signal transducing Ser/Thr kinases in cells that relay a cascade of signals, triggered 
by external stimuli. The flow of information is usually mediated by multiple 
phosphorylation steps, beginning at the plasma membrane and proceeding to one 
or more cytoplasmic or nuclear substrates. There are three main branches of 
MAPK pathways which are widely studied: extracellular signal-regulated kinase 
(ERK), p38 MAPK and c-Jun NH2-terminal kinase (JNK) pathways. Each of these 
pathways is composed of a three-step signaling network of conserved serially 
acting kinases termed as MAPKKK (MAPK kinase kinase), MAPKK (MAPK kinase) 
and the final effector MAPKs, which through their phosphorylation of multiple 
substrates govern functions related to gene expression, cell growth, proliferation, 
mitosis, metabolism, migration, survival and apoptosis (pictorial representation in 
Fig. 5) [for more details, please refer to (246-248)]. 
 
2.5.1 ERK 
 
The ERK module of the MAP kinases has a predominant role in cell survival and 
proliferation. It is mostly activated by different types of growth factors like the 
platelet-derived growth factor, epidermal growth factor, and nerve growth factor 
as well as in response to insulin. The activation starts by ligand binding at cell 
surface receptor tyrosine kinases which leads to a sequence of events that activate 
different Raf protein isoforms, which are the primary MAPKKKs in this module. 
Activated Ras then binds and phosphorylates MEK1/2 (the MAPKK in this 
pathway) which in turn phosphorylates the effector MAPKs, ERK1/2. Activation of 
this module leads to a significant amount of nuclear localization of ERK. Some of 
the important nuclear substrates of ERK are c-Fos and Elk-1, which have roles to 
play in cell cycle progression and survival. MEK1/2 inhibitors like PD98059 and 
U0126 which preferentially interact with the unphosphorylated forms of the 
kinase have been used to delineate the function of this pathway in different 
biological phenomena [reviewed in (246, 249)]. 
 
2.5.2 p38 MAPK 
 
p38 MAPK has a major role in inflammatory immune responses and apoptosis. 
Four different isoforms (p38?, p38?, p38? and p38?) have been discovered. This 
pathway is strongly activated by a variety of different stress stimuli like UV 
irradiation, oxidative stress, hypoxia, ischemia; and inflammatory cytokines like 
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TNF (Tumor necrosis factor)-? and IL-1. Cytokine stimuli promote TRAF (TNF-
receptor Associated Factor) protein recruitment to the intracellular domains of 
their cognate receptors. This leads to the activation of the initial MAPKKKs in this 
cascade, which include MEKK1-3, MLK2/3, ASK1, Tpl2 etc. In addition, this 
activation can also be triggered by certain GPCRs (G-protein Coupled Receptors), 
as well as Rho family GTPases like Rac and Cdc42. MKK3/6 are the MAPKKs in this 
cascade that form functional complexes with the different p38 isoforms, leading to 
their activation. p38 MAPKs in turn phosphorylate different cytoplasmic (MNK1/2, 
Bax, Tau etc.) and nuclear substrates (ATF1/2/6, p53, MSK1/2, GADD153 etc.) that 
are responsible for various proinflammatory and apoptotic responses. SB203580 
and SB202190 are compounds that target the activity of p38? and p38? isoforms 
by competitively inhibiting ATP binding and have been used in numerous studies 
to shed light on the role of the p38 MAPKs in different processes [reviewed in (246, 
250)]. 
 
 
Figure 5. Three-tiered MAPK signaling cascade. Schematic diagram showing the three 
main groups of the MAPK signal transduction system – ERK, p38 and JNK. Some of the main 
kinases at each stage are shown, along with the inhibitors commonly used to study their effects 
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in different biological scenarios. [Reprinted from (1) with permission from the American 
Society for Microbiology]. 
 
 
2.5.3 JNK 
 
There are three isoforms of JNK [also called stress-activated protein kinase 
(SAPK)], which similar to the p38 MAPKs are strongly activated by external stress 
signals like DNA damaging agents, ionizing radiation, heat shock, cytokines, UV 
irradiation, DNA and protein synthesis inhibitors etc. After being activated by 
upstream MAPKKKs common to the p38 MAPK pathway, MKK4 and MKK7 
(MAPKKs of this module) co-operatively phosphorylate and activate the JNKs. 
Similar to ERK and p38 MAPK, JNK also depicts a predominant, but not exclusive 
nuclear localization subsequent to activation. JNK also has multiple downstream 
substrates that participate in cellular functions related to cell proliferation 
(especially in hematopoietic cells) and in the intrinsic apoptotic response to 
cellular stress. One of the well-characterized substrates of JNK is the transcription 
factor c-Jun, which together with c-Fos (activated by ERK) form functionally active 
AP (Activator protein)-1 complexes that modulate gene expression related to cell 
cycle progression by interacting with their AP-1-binding sites. SP600125 and 
AS601245 are two reversible ATP-competitive inhibitors that inhibit the activity of 
the JNKs [reviewed in (246, 251)]. 
 
2.5.4 Role of MAPK signaling in viral life cycles 
 
The functions carried out by MAPK signaling are quite complex in nature and are 
often context and cell-type specific. Different viruses either stimulate or suppress 
MAPK signaling in order to favor their replication. We will briefly take a look at the 
role of MAPK signaling in the life cycles of some important RNA viruses. 
 
HIV 
HIV is the causative agent of AIDS and has a complex replication strategy involving 
reverse transcribing its RNA genome into DNA and integrating it into the host 
genome (252). Additionally, HIV has several regulatory proteins like Tat, Rev, Nef, 
Vif, Vpu and Vpr, which have diverse roles in the viral life cycle, which influence its 
ability to sustain a productive infection and cause disease. The production of pro-
inflammatory cytokines like IL-10 during HIV infection is induced by the Tat 
protein and depends on ERK and p38 MAPK, through phosphorylation of the 
CREB-1 transcription factor (253). In striatal neuronal cells, Tat protein induced 
cell death by JNK-dependent caspase-3 activation (254). HIV Vpr protein is 
primarily responsible for regulating the import of the HIV-1 pre-integration 
complex into the nucleus (255), but can also induce cell cycle arrest and apoptosis 
by downregulating ERK (256). HIV-1 Nef protein mediates bystander killing of 
both CD4+ and CD8+ T-cells through upregulation of the Fas ligand, a process that 
requires p38 and Nef-induced AP-1 activation. Additionally, specific inhibitors of 
the p38 MAPK pathway led to reduced bystander damage of CD8+ cells in vitro 
(257).  
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IAV 
IAV is a negative-sense RNA virus that causes respiratory infections, resulting in 
mild to severe flu-like symptoms leading to thousands of deaths and millions of 
hospitalizations every year (258). MAPK signaling and in particular, the ERK 
signaling pathway has a proviral role in the IAV life cycle in infected host cells 
(259). Virus replication was not only inhibited by specific inhibitors and dominant 
negative mutant kinases of this pathway, but also enhanced by active kinase 
mutants, both in vitro as well as in vivo in mice (259-261). The nuclear export of 
viral RNP (ribonucleoprotein) complexes is impeded when this pathway is blocked 
(259). Expression of the viral HA protein and its arrangement as lipid raft domains 
requires ERK activation and coincides well with RNP export, suggesting that ERK 
activation might be crucial for IAV budding (262). p38 MAPK pathway in IAV 
infection is responsible for the induction of the inflammatory response, leading to 
production of cytokines like RANTES and IL-8 (263). As opposed to the ERK 
pathway, the JNK pathway is crucial for the innate antiviral response and 
regulating the expression of IFN-? and defects in this pathway led to increased 
virus production. Additionally, IAV triggered AP-1 expression also takes place 
through JNK phosphorylation of its transcription factors c-Jun and ATF-2. IAV-
induced JNK activation correlated with the accumulation of viral RNA in infected 
cells (264). 
 
SARS-CoV (Severe Acute Respiratory Syndrome-Coronavirus) 
SARS-CoV is a single-stranded positive-sense RNA virus and has a large genome of 
~30kb (265). This virus which spread globally in 2003, resulting in a worldwide 
pandemic, causes severe respiratory illness and pneumonia (266) with a ~9.6%  
case fatality rate in infected patients  (http://www.who.int/csr/sars/en/). SARS-
CoV infection results in ERK1/2 phosphorylation, which is a thought to promote a 
prosurvival signal to the cells (267). At the same time, p38 MAPK activation in 
SARS-CoV infected cells promotes CPE and cell death (268). There is conflicting 
information about the precise role of p38 MAPK activation in the context of SARS-
CoV infection. While apoptosis is normally observed with this pathway in virus-
infected cells, several downstream pro-survival targets of p38 MAPK like CREB 
(cyclic AMP response element binding protein) and HSP27 were also reported to 
be activated (268). JNK activation occurs late in SARS-CoV infected cells and is 
thought to be involved in persistent infection of the cells (268). Overall, SARS-CoV 
infection seems to activate both prosurvival and apoptotic cell signaling MAPK 
pathways, but more research needs to be done to characterize the biological 
significance of these activations. 
 
In addition to the above-mentioned examples, several RNA viruses like HCV (269), 
DENV (270, 271), WNV (272), EBOV (273) and RSV (274) as well as pathogenic 
DNA viruses like Epstein-Barr virus (275, 276), HBV (269), human papilloma virus 
(277) and herpesviruses (278) activate different branches of the MAPK signaling. 
This activation can either serve to prolong the life of the infected cells in order to 
maximize the production of progeny virions or to trigger apoptosis later in the 
infectious cycle. Despite its seemingly important role across viruses of different 
families, MAPK signaling in the context of alphavirus infection is a relatively 
underexplored area and deserves more attention. 
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3. AIMS OF THE STUDY 
 
At the beginning of this study, CHIKV had spread to Europe and therefore, urgent 
intervention measures were needed to counter this re-emerging alphavirus.  
 
This study aimed to miniaturize a previously developed CHIKV replicon cell line 
(85) to a 384-well plate format for high-throughput screening. Once the assay was 
set up, the aim was to screen drugs previously approved for other indications or 
those in clinical trials for antiviral activity against the replication stage of the 
CHIKV infectious cycle (I). 
 
The next step was to characterize the mechanism of a relatively non-toxic inhibitor 
obtained in the screen – berberine (BBC) and to assess its effectiveness in vivo in a 
CHIKV mouse model (II). 
 
An anti-cancer molecule, obatoclax (OLX) was shown to be antiviral against IAV 
and also against SINV (279). In the final part of the study, the objective was to 
determine the effectiveness of obatoclax against CHIKV and to characterize its 
mode of action (III). 
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4. MATERIALS AND METHODS 
 
Most of the methods used in this study are described in the original publications as 
indicated in Table 2 
 
Table 2. Materials and methods used in this thesis 
Materials and Methods Publication 
Cell Culture  
A549 III 
BHK-21 I, II, III 
C6/36 II 
CRL-2522 II 
HEK (human embryonic kidney)-293T II 
HOS (human osteosarcoma) II, III 
Huh (human hepatoma) 7.5 I, II 
Vero E6 II 
  
Viruses  
wild type CHIKV (LR2006 OPY1) I, II, III 
CHIKV-Rluc I, II, III 
CHIKV-Gluc II 
CHIKV-CNR20235-Gluc II 
CHIKV-SGP11-Gluc II 
CV (coxsackievirus)-A9  III 
E (echovirus)-6 III 
E-7 III 
ONNV II 
wild type SFV4 I, III 
SFV-Rluc III 
SFV-ts9-Rluc II, III 
WNV III 
YFV 17D I, III 
ZIKV III 
  
Virological and cell culture methods  
Antiviral dose response assay I, II, III 
Cell viability assays I, II, III 
Luciferase measurements I, II, III 
Plaque assay titration I, II, III 
Plaque purification III 
ts9-Rluc Entry assay II, III 
Nucleic acid techniques  
Cloning III 
Comparative real-time PCR I 
DNA and RNA isolation I, II, III 
DNA transfection I, II 
Northern blotting I, II, III 
PCR III 
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Quantitative real-time PCR II 
Sanger sequencing III 
Site-directed mutagenesis III 
  
Immunological methods  
Human phosphokinase array II 
Western blotting I, II, III 
  
Data Analysis  
Aida Image Analyzer I 
HistoQuest II 
ImageJ II 
Odyssey Infrared Imaging System I, II, III 
OriginPro I, II, III 
SkanIT Varioskan software I, II, III 
  
Plasmid Constructs  
P1234 (CHIKV) II 
P123Z4 (SFV) II 
pCMV-SFV4 III 
pSP6-ICRES-CHIKV (wild type and Rluc) I, II, III 
pUC18_Stluc II 
pUC18_T short II 
T7-Rluc-Tom II 
  
Antibodies  
Anti-?-actin I, II, III 
Anti-CHIKV capsid II, III 
Anti-CHIKV E2 I, II, IIII 
Anti-CHIKV nsP1 I, II, III 
Anti-CHIKV nsP3 II, III 
Anti-phospho Akt II 
Anti-phospho ERK1/2 II 
Anti-phospho JNK1/2/3 II 
Anti-phospho p38 II 
Anti-total Akt II 
Anti-total ERK1/2 II 
Anti-total JNK1/2/3 II 
Anti-total p38 II 
  
Compounds  
Abamectin I 
ABT-199 III 
Amphotericin B I 
Atovaquone I 
Bafilomycin A1 II, III 
Berberine chloride I, II 
Bifonazole I 
Bromocriptine  I 
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Cerivastatin lactone I 
Chlorpromazine II, III 
Clofoctol I 
Clotrimazole I 
Efavirenz I 
Fenretinide I 
Ivermectin I 
Miconazole I 
Obatoclax mesylate III 
SB203580 II 
SP600125 II 
Triclabendazole I 
TW-37 III 
U0126 II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 33 
 
5. RESULTS AND DISCUSSION 
 
5.1 CHIKV replicon screening platform and its optimization for 
high throughput screening (I) 
 
CHIKV re-emerged between the years 2004 – 2006 on a massive scale and spread 
throughout tropical Africa and Asia (124, 125). Later, the outbreaks in Italy and 
France in 2007 and 2010 respectively (126, 127), garnered a lot of attention 
worldwide, leading to an overwhelming response from many research groups and 
the organization of focused research consortia. As part of one such group, the 
ICRES (Integrated Chikungunya Research) European Union-funded consortium, the 
SFV group set out to develop screening tools to discover bioactive compounds with 
antiviral activity against CHIKV and identify potential antiviral drug candidates. In 
countries where CHIKV is not endemic, the virus needs to be handled under high 
containment BSL (Biosafety Level)-3 conditions. These facilities are not only 
tedious to work in, but also expensive to maintain.  
 
As an alternative to using live CHIKV infections, Pohjala and co-workers 
established a BHK-derived cell line stably expressing CHIKV replicon (85). Plus 
strand RNA virus replicons are based on a bicistronic RNA molecule, where one 
cistron encodes for a reporter and a selectable marker and the other cistron 
encodes for the viral non-structural proteins. Here Renilla reniformis luciferase 
gene was cloned as a fusion protein with nsP3 and served as a readout for viral 
protein expression levels and indirectly for replication. Puromycin 
acetyltransferase for antibiotic selection and EGFP (Enhanced Green Fluorescent 
Protein) as a visual marker were included under the subgenomic promoter of the 
replicon. Additionally, a Pro718Gly mutation and a 5 amino-acid insertion in nsP2, 
obtained during the selection process, was necessary to confer a non-cytotoxic 
phenotype and ensure survival of the cells expressing the replicon. This tool was 
used in a 96-well plate format to screen a small set (~350) of natural compounds, 
resulting in a few compounds effective at low micromolar concentrations. These 
compounds were tested for their antiviral activity against SFV (the prototype 
relatively non-pathogenic alphavirus) and also against infectious CHIKV (85). 
Replicon systems have been useful in circumventing the problem faced with 
handling or culturing wild type infectious viruses. With HCV, it was a challenge for 
many years to obtain a suitable system that would allow screening for antiviral 
drugs, until the development of the replicon system which allowed replication of 
the non-structural proteins to very high levels in Huh-7 cells (280, 281). The 
replicon system has since been used for antiviral screening against different plus-
stranded RNA viruses (178, 282, 283). Replicon systems although amenable for 
high throughput screening have obvious limitations as well. They restrict the 
screen to compounds that target only the replication cycle and miss out any 
potential hits which could affect entry, maturation and exit processes of the viral 
life cycle. Screening facilities within high containment laboratories (284) or the use 
of an attenuated vaccine strain (225) has allowed for assessing the entire viral life 
cycle for possible targets. High content image analysis has been useful in this 
context where either reporter viruses containing fluorescent tags (224) or analysis 
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by subsequent immunofluorescence assays (285) have been used to screen for 
antiviral drugs or host factors critical for virus replication. 
 
The CHIKV replicon screening platform was optimized and miniaturized for a 384-
well plate format at the high-throughput screening facility at the Institute for 
Molecular Medicine Finland (FIMM). The assay was carried out in an automated 
manner using a BeckmanCoulter Integrated Robotic System and compounds were 
added with precision to each target well at 10 μM concentration using an acoustic 
dispensing system. Assay conditions like cell number, assay medium and volume of 
detection reagents to be used were optimized. We obtained a Z? score of 0.7 for the 
assay which is higher than the threshold of 0.5, indicating that the assay was 
suitable. The Z? score is a statistical measure of the suitability of a high-throughput 
assay, to assess if differences seen in treated samples are of significant value as 
compared to the positive and negative controls (286). Also, the coefficients of 
variation were for the positive control (6-azauridine) and negative control (0.1% 
DMSO) were 11% and 7% respectively, suggesting that these compounds served as 
appropriate controls for the assay (I). 
 
5.2 Identification of novel antiviral drugs with broad-spectrum 
anti-alphaviral activity at low micromolar concentrations (I, 
III) 
 
The high throughput assay screened ~3000 bioactive compounds from three 
different libraries – the NIH Clinical Collection, ENZO FDA-approved drug library 
and the MicroSource Spectrum library. These were compounds either in clinical 
use or clinical trials against other indications, with the intent of repurposing drugs 
with known targets/effects as antivirals against CHIKV. Screening libraries 
containing previously characterized or approved compounds has a distinct 
advantage in terms of knowing the targets and pharmacokinetic properties of 
these compounds in animal models. This approach of attempting to repurpose 
compounds for antiviral use has been used by several different groups conducting 
high throughput screens for inhibitors (225, 287). Using stringent selection criteria 
and further primary validation, the list of candidate drugs was narrowed down to 
27 compounds (Table S1, Figs. S1A, S1B; I). Additionally, all compounds showed < 
75% toxicity in the replicon-containing cells over a relatively long period of 48 h. 
This ensured that compounds which were purchased for resupply analysis had 
considerable selectivity in their antiviral activity. One of the compounds, 
amphotericin B turned out to be a false positive, inhibiting the reporter luciferase 
enzyme itself (Figs. 1D & S2; I). This calls for caution while interpreting reporter 
expression data in high-throughput screening.  
 
Secondary validation with infectious CHIKV-Rluc virus trimmed the list further to 
seven compounds with strong antiviral activity, without adverse cytotoxic effects. 
Next, these compounds were validated in Huh 7.5 cells, which confirmed their 
effectiveness in a human cell line. All the compounds showed similar or lower EC50 
values in Huh 7.5 cells as compared to BHK-21 cells (Table 1; I). Cerivastatin was 
the only exception. This compound which targets the HMG-CoA (3-hydroxy-3-
methyl-glutaryl-coenzymeA) reductase enzyme and reduces cholesterol 
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biosynthesis did not inhibit CHIKV replication in Huh 7.5 cells, probably due to 
increased cholesterol levels in the used hepatoma cells (288). Out of these eight 
compounds, only abamectin (EC50_BHK = 1.5 μM), ivermectin (EC50_BHK = 0.6 μM) and 
berberine (EC50_BHK = 1.8 μM) reduced the production of infectious viruses, 
although some other inhibitors like bromocriptine showed marginal reduction in 
viral RNA synthesis and both bromocriptine and cerivastatin showed a weak 
reduction in viral protein expression (Fig 2; I). The higher sensitivity of the 
luciferase assay can amplify small changes in protein expression. Most likely, these 
changes were not enough to result in a significant reduction in progeny virion 
production. Fenretinide, one of the hits in our screen, proved to be more effective 
against YFV, a flavivirus. This observation was later confirmed by two groups that 
reported fenretinide to inhibit the replication of DENV and other flaviviruses and 
also offer protection against DENV in vivo (289, 290). It was proposed that 
fenretinide interfered with the recognition of DENV NS5A by cellular nuclear 
import proteins and modulated the unfolded protein response (UPR) to impede 
virus replication (290).  
 
We noticed a discrepancy in the inhibition profile for abamectin, ivermectin and 
berberine. Both abamectin and ivermectin completely abolished viral protein 
expression and RNA synthesis levels and also significantly reduced viral titers. On 
the other hand, berberine which did not have a strong effect on viral RNA synthesis 
and protein expression, reduced viral titers significantly, prompting us to 
investigate this further in a time-of-addition experiment (Fig. 2; I). The results of 
this experiment correlated with our previous observations and showed that 
berberine indeed had an additional late effect on the maturation or exit phase of 
the viral life cycle (Fig. 3; I). At first glance, it seems contradictory that a compound 
obtained through screening only for inhibitors that target the viral life cycle has a 
predominant effect of virus particle production. Nevertheless, berberine seemed to 
have a dual mode of action, where viral protein production and RNA synthesis was 
also reduced to some extent and could be why it was picked up in our initial screen 
(Figs. 1 & 2; I). However, at this stage, we had strong suspicions and indications 
from recent studies that berberine most likely targets host factors essential for a 
productive viral infection, which reflected in the reduction of different viral 
components. This was addressed later in our follow-up study (II).  
 
In conclusion, the CHIKV replicon cell line represents a feasible platform to rapidly 
screen thousands of different compounds that target alphavirus replication. 
Nevertheless, there are also limitations with this system. There can be false 
negatives that might target viral processes other than replication. Secondly, the 
non-toxic phenotype of the CHIKV replicon abrogates nsP2 translocation to the 
nucleus, which does not represent the scenario of live virus infection. Besides, the 
parental cell line, BHK-21 is IFN-defective and does not accurately portray the 
cellular environment in CHIKV infections. We tried to address some of these 
limitations in our subsequent study (II).  
 
The work conducted as part of this dissertation also revealed another small-
molecule compound – obatoclax possessing broad-spectrum activity against 
different alphaviruses. Obatoclax, an anti-cancer drug was first reported to have 
antiviral activity against IAV and several other viruses, including SINV (279). We 
report that obatoclax was highly active against both SFV (EC50 = 0.23 μM) and 
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CHIKV (EC50 = 0.04 μM) with remarkably high selectivity indices (Table 1; III) and 
also characterized its mode of action (III), which will be discussed in detail below.  
 
Altogether, these molecules represent novel antivirals against CHIKV and other 
alphaviruses, which are effective at low micromolar concentrations and could 
serve as starting points for further drug development. Although, ivermectin 
(structural analogue of abamectin) was quite toxic in Huh 7.5 cells (Table 1; I), it 
has been in clinical use against different parasitic diseases like onchocerciasis and 
elephantiasis (291), suggesting that ivermectin is well tolerated in humans. 
Further work needs to be done to evaluate its effectiveness against alphaviruses in 
other cell lines and in animal models. The modes of action of berberine and 
obatoclax were explored further and will be described later. 
 
5.3 CHIKV-induced MAPK signaling (II) 
 
In our pursuit to dissect the mechanism of berberine, we serendipitously stumbled 
on to signaling pathways activated by CHIKV. Published literature on berberine 
seemed to be conflicting and contradictory and quite often cell-type or context-
specific. Therefore, a human phosphokinase array was used to assess the effects of 
CHIKV infection and berberine treatment on the activation of a panel of 48 cellular 
kinases and the phosphorylation of their substrates. This array helped to depict for 
the first time, the robust activation of the major MAPK signaling pathways – ERK, 
p38 MAPK and JNK by CHIKV infection (Figs. 5A, 5B & 6E; II).  
 
Earlier, MAPK activation by alphavirus infection was shown for SINV (292) and 
VEEV (293). Similar activation by CHIKV indicates the conserved nature of these 
pathways in the alphavirus life cycle. Contrarily, ERK signaling was found to be 
antiviral against SINV in Aedes aegypti Aag2 cells, and this pathway was triggered 
in the insect gut epithelium by the insulin present in the vertebrate blood meal 
(294). Arbovirus infections progress differentially in mammalian and insect cells 
and this may be reflected in distinct signaling patterns during virus infection. ERK 
signaling seems to confer a prosurvival state to infected cells in the life cycle of 
different viruses (259, 269, 295). ERK signaling was also shown to be crucial in IAV 
budding from infected cells (262). ERK exhibits a typical biphasic activation 
pattern during infection with several different viruses – at the time of viral binding 
or entry and next coinciding with virus replication or egress (296-298). It will be 
interesting to know if this pattern is also exhibited by CHIKV and assess the effects 
of inhibitors of the ERK pathway on CHIKV entry. Indeed, for VEEV, ERK activation 
was noticed at early time points of infection (293). In our analysis, we chose a time 
point based on nsP3 expression levels in order to visualize the overall effect on 
signaling pathways as a result of CHIKV replication (Fig. 5; II). One of the 
substrates of Erk is the transcription factor, c-Fos, the phosphorylation of which 
was reported to be upregulated by HCV (299) and coxsackievirus B3 (300). It will 
be interesting to analyze the effect of c-Fos activation in the context of CHIKV 
and/or alphavirus infection. The upstream MEK1/2 inhibitor U0126 could 
significantly reduce viral titers under high MOI (multiplicity of infection) 
conditions, even though there seemed to be only a marginal effect on viral protein 
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expression (Fig. 6; II). This suggests that the ERK pathway might be essential for 
CHIKV maturation/egress. 
 
SINV was also shown to activate the p38 MAPK and JNK at later time points (292). 
These pathways are usually induced by pro-inflammatory cytokines and cellular 
stress and are responsible for regulating immune response and apoptotic signaling 
(246). However, Nakatsue and colleagues showed that SINV infection leads to the 
phosphorylation of HSP27, which is usually associated with cell survival (292). We 
did not observe HSP27 phosphorylation with CHIKV infection in the 
phosphokinase array (data not shown), which might suggest differences in the 
eventual fate of MAPK activation between SINV and CHIKV. Another probable 
explanation is that these differences could be cell-type specific: the SINV study was 
performed in Vero cells (292), whereas we used IFN-competent HOS (human 
osteosarcoma) cells. There are quite a few examples of viruses or viral proteins 
which activate (301, 302) or inhibit (303, 304) JNK and its downstream 
transcription factor, AP-1 which seems to have stimulus-specific cell proliferative 
or growth arrest functions. For some viruses like JEV, it was shown that the UPR 
initiated due to high level viral protein expression in the endoplasmic reticulum 
results in apoptosis in a p38 MAPK and JNK dependent manner (305, 306). It 
would be interesting to assess the effects of alphavirus-induced UPR on MAPK 
signaling. The importance of the JNK cascade in the CHIKV life cycle was 
highlighted by a 2 log reduction in viral titers in response to treatment with a 
specific JNK inhibitor, SP600125 (Figs 6C & 6D; II). Unlike the MEK1/2 inhibitor, 
treatment with SP600125 also reduced virus-mediated reporter protein 
expression, suggesting that the JNK pathway could be subverted by CHIKV 
infection for multiple purposes. Treatment with the p38 MAPK inhibitor, 
SB203580 seemed to activate the ERK and JNK pathways and did not show any 
reduction in viral titers. This was surprising, as virus-mediated reporter 
expression had been significantly reduced on SB203580 treatment (Figs. 6C – 6E; 
II). This made us conduct a comprehensive literature review, and indeed there 
were reports of SB203580 and one of its metabolites cross-activating the ERK and 
JNK pathways (307, 308). This could in turn compensate for the loss of p38 activity 
in SB203580 treated cells and therefore no reduction in viral titers is seen, 
whereas in a luciferase based system, small differences can sometimes be 
amplified. In the luciferase assay, there is no assembly or budding and it is likely 
that inhibitions at the luciferase levels (thus, on replication) were “compensated” 
in the infection assay (by not having impact on assembly/budding). This 
underscores the importance of assessing viral titers in addition to reporter protein 
expression data to study the effect of different inhibitors on the viral life cycle. This 
study emphasizes the potential of cellular MAP kinases as therapeutic targets 
against CHIKV and other pathogenic alphaviruses. Indeed, our observations were 
independently confirmed by another study screening for host factors affecting 
CHIKV replication, where some of the upstream kinases in the p38 MAPK and JNK 
modules were implicated to have proviral functions. The same study also showed 
that FDA-approved drugs targeting receptor tyrosine and other upstream kinases 
activating MAPK, like sorafenib, tivozanib and linifanib showed antiviral activity 
against CHIKV with good therapeutic indices (224). 
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5.4 Berberine as a novel antiviral modulating host signaling
pathways (II) 
 
Berberine is an isoquinoline plant-derived alkaloid that has been used in 
traditional Chinese and Ayurvedic medicine for thousands of years (309, 310). 
Additionally, this compound has been in clinical trials and in clinical use for a wide 
variety of disorders like diabetes, hypercholesterolemia, and different forms of 
cancer and has also been shown to possess anti-inflammatory and anti-microbial 
properties (309, 311). More importantly, there have been several reports 
describing its antiviral properties against viruses from different families like HCMV 
(312), HSV (313), HPV (314) and RSV (315), some of them implicating different 
MAPKs as probable targets of berberine. As described above, CHIKV infection 
induced the activation of the major MAPK signaling pathways. In our initial array 
as well as in confirmatory immunoblots performed in two different cell lines, 
berberine was capable of concomitantly reducing MAPK activation (Figs 5B & 6E; 
II). This was in line with earlier observations where berberine reduced p38 MAPK 
activation in RSV infection and JNK activation in HSV-1 infection.  
 
 
 
Berberine was also capable of reducing virus-independent, serum-induced ERK 
activation (Fig. 7; II), demonstrating that berberine affects host-processes which in 
turn could inhibit virus replication and consequently dampen other interconnected 
pathways. We did not observe any effect of berberine treatment on anisomycin 
(protein synthesis inhibitor)-induced JNK activation (data not shown). 
Nevertheless, we did notice reduction in basal JNK signaling in unstimulated cells 
(Fig. 6E; II). Further work needs to be done to elucidate the precise molecular 
target of berberine. 
Earlier, it was shown that both SFV and CHIKV differentially activate the PI3K-Akt 
pathway. SFV is a strong inducer of the pathway, whereas SFV-?50 virus (mutant 
virus lacking 50 phosphorylated amino acids in the HVD of nsP3) as well as CHIKV 
only moderately activated this pathway (46). In our study, we also observed the 
CHIKV-induced Akt phosphorylation and its reduction in the presence of berberine 
(Figs. 5B & 6E; II). Berberine was found to significantly reduce SFV titers under 
low MOI conditions (Fig. 4A; I), but under high MOI conditions, berberine could 
not reduce the robust activation of Akt by SFV [Fig. 6 (316)]. This might 
Fig. 6 SFV Akt-phosphorylation 
profile in the presence of 
berberine. BHK-21 cells were mock-
infected or infected with SFV wild 
type (wt) and SFV-?50 viruses at 
MOI 10 with or without 5 μM 
berberine (B1). 5 h p.i., infected cells 
were lysed and processed for 
Western blot analysis using 
antibodies against SFV nsP3, 
phospho-Akt, total Akt and actin. 
Representative data set from two 
independent experiments. 
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correspond to the higher EC50 value (19.5 μM) obtained for berberine with SFV-
Rluc virus (data not shown), where luciferase is expressed as a fusion protein with 
nsP3. Contrarily, the moderate Akt phosphorylation induced by SFV-?50 was 
drastically reduced by berberine, similar to that observed for CHIKV. This suggests 
that the effect of berberine on alphavirus-induced Akt phosphorylation depends on 
the Akt activation capacity of the virus in question and does not correspond to the 
observed reduction in viral titers. Berberine remains an enigmatic compound with 
myriad effects on multiple interconnected signaling pathways and this might be a 
reason for its relative non-toxic nature. 
 
In study II, we overcame some of the limitations of our previous work. Berberine 
was proven to be effective against CHIKV in different IFN-competent human cell 
lines at high selectivity indices (Fig. 1; II) and worked against a variety of 
circulating CHIKV strains (Fig. 2; II). Additionally, berberine was antiviral against 
CHIKV even under high MOI conditions, reducing viral protein expression and 
titers. Berberine did not have a remarkable effect on RNA synthesis at the same 
concentrations (Fig. 3; II), highlighting once again that berberine does not 
interfere directly with the viral replication process. However, the defect may occur 
at a post-RNA synthesis stage by probably affecting host factors needed for viral 
structural protein expression or maturation and egress. This was also confirmed 
by the observation that berberine did not affect alphavirus entry or the trans 
replication of separately provided template RNA by SFV and CHIKV replicase 
proteins (Fig. 4; II). 
 
5.5 The in vivo efficacy of berberine (II) 
 
No antiviral showing promise in cell culture models can progress further, without 
proving to be efficacious in vivo. Therefore, berberine was tested in a mouse model 
that mimics the arthritic and myalgic manifestations seen during CHIKV infection 
in humans. Four-week-old female C57BL6/J mice were infected with CHIKV at the 
ventral side of the right hind footpad. This model uses footpad swelling as an 
indicator of CHIKV-induced inflammatory disease. We sought to replicate a typical 
antiviral drug regimen taken after onset of acute disease, treating the infected mice 
24 h post-infection. Berberine was capable of controlling viral RNA levels in serum 
as compared to control-treated mice. Although this reduction in RNA levels was 
not statistically significant, it was enough to significantly reduce disease score as 
compared to the control mice at all days of peak disease severity. On day 6 p.i., joint 
swelling was reduced to marginal levels. Additionally, a marked reduction in 
inflammatory cell infiltrates in the infected joint footpad was observed in 
berberine-treated mice (Fig. 8; II). These results highlight both the antiviral and 
anti-inflammatory properties of berberine. 
 
The observed LD50 for berberine in mice is ~57 mg/kg (317), which is 
considerably higher than the dose of 10 mg/kg we employed in our study. 
Although, we did not achieve statistically significant differences in all of the 
parameters measured, this could well be due to the specific dosage conditions. In 
several studies validating antivirals against CHIKV in the same or different mouse 
models, compounds were also administered prophylactically (196, 230, 318), 
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which may have contributed to its efficacy. In our study, berberine was 
administered through the intra-peritoneal route due to its reduced oral 
bioavailability, which may not be ideal. Several groups are working on methods to 
improve the bioavailability of this compound (319, 320). Besides, further 
optimization of this compound may lead to improved compounds with better 
antiviral properties and enhanced bioavailability and tolerance. Therefore, further 
investigation is needed with berberine in terms of dosing, treatment schedules and 
assessment of immune functions. Nevertheless, berberine is now added to the list 
of the few compounds that have demonstrated antiviral efficacy against CHIKV in a 
mouse model. 
 
5.6 Obatoclax as a novel viral fusion inhibitor (III) 
 
A derivative of bacterial prodigiosin, obatoclax was originally designed as an anti-
cancer drug. Bcl-2 family proteins control cellular fate by regulating mitochondrial 
permeabilization and subsequent apoptosis. The prosurvival members of the Bcl-2 
family like Bcl-2, Bcl-XL and Mcl-1 (myeloid leukemia cell differentiation protein-
1) bind and sequester their proapoptotic counterparts, Bak (Bcl-2 homologous 
antagonist killer) and Bax (Bcl-2 associated X protein). BH3-only proteins 
(members of the Bcl-2 family that contain only a BH3 domain) like NOXA, Bim (Bcl-
2-like protein 11) and Bad (Bcl-2-associated death promoter) dock their ?-helical 
BH3 domain into a hydrophobic groove of the prosurvival protein, thereby 
disrupting their interaction with Bak/Bax [reviewed in (321)]. Obatoclax is a BH3 
domain mimetic that antagonizes the anti-apoptotic protein, Mcl-1, a protein that is 
often over-expressed in cancer cells (322, 323). Only a few years back, it was 
shown to possess antiviral activity against IAV. In the same study, obatoclax was 
also tested against other RNA and DNA viruses with differential results. In 
particular, it was highly effective against SINV at low concentrations (279). This led 
us to assess the effectiveness of obatoclax against the other alphaviruses – SFV and 
CHIKV. 
 
The low EC50 values (0.04 μMCHIKV), coupled with high selectivity indices against 
these viruses (Table 1; III) highlights the potential of obatoclax for further drug 
development. Indeed, the plasma level concentrations in clinical trials reached a 
Cmax of 0.4 μM (324, 325), indicating that obatoclax could offer a probable 
prophylactic and therapeutic alternative against CHIKV and other alphaviruses. 
Denisova and co-workers had shown that obatoclax interferes with the entry and 
uptake of IAV and suggested the targeting of Mcl-1 to be the mode of action. 
Indeed, silencing Mcl-1 reduced IAV protein expression (279). In our study, we also 
noticed a predominant effect of obatoclax on the early phase of alphavirus 
infection (Fig. 2; III). An entry assay performed with temperature-sensitive SFV-
ts9 mutant clearly showed that obatoclax inhibited alphavirus entry (Fig. 3A; III). 
Time of addition assays measuring both viral titers as well as luciferase signals in 
the entry assay showed that obatoclax gradually loses its effect when added at later 
time points of infection (Figs. 2C, 2D & 3B; III). 
 
The most remarkable observation came with the neutral red retention assay, 
which depicted the swift neutralization of the acidic organelles brought about by 
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obatoclax treatment (Fig. 4A; III). Surprisingly, the basic nature of obatoclax was 
sufficient to neutralize an acidic buffer of pH 5.5. This precluded reliable 
conclusions from the endosomal bypass assay, forcing us to modify the protocol 
and include a treatment schedule beginning after the induction of fusion at the 
plasma membrane, which was able to rescue majority of the viruses from 
inhibition by obatoclax (Fig. 4B; III). Obatoclax could represent a new class of 
lysomotrophic agents representing viral fusion inhibitors. This finding represents a 
new property of this compound and is independent of its antagonism of Mcl-1. As 
controls, we tested other compounds that inhibited the same targets. These 
compounds (TW-37 and ABT-199) neither affected virus entry nor neutralized the 
acidic environment of endolysosomal compartments (Fig. 6; III). While study III 
was being prepared, three different groups observed the loss of endosomal 
acidification induced by obatoclax, providing independent corroboration for our 
observations (326-328). Furthermore, we showed that other viruses dependent on 
low pH for fusion (WNV, YFV and the re-emerging ZIKV) were inhibited by 
obatoclax to a similar extent (Table 2 & Fig. S3; III). On the other hand, certain 
viruses from the Picornaviridae family (CV-A9, E-6 and E-7), which do not require 
low pH for entry or uncoating, were not affected by obatoclax treatment (Table 2 
& Fig. S4; III). Obatoclax was shown to accumulate in lysosomes (326) and also to 
cause lysosomal clustering in some other cell types (328). Nevertheless, the exact 
molecular mechanism of by which obatoclax mediates endolysosomal 
neutralization needs further investigation. Further lead optimization to develop 
related molecules with lower toxicity could propel obatoclax to become an 
effective broad-spectrum antiviral drug. The anti-malarial drug chloroquine which 
operates with a similar mechanism has also shown promise with numerous viruses 
in vitro, but has met with very little success in vivo (329). 
 
5.7 Isolation of drug-resistant SFV mutants (unpublished, III) 
 
One of the classical methods to gain insight into the putative mode of action of an 
antiviral compound, is the isolation of drug-resistant mutants. In this process, the 
virus in question is usually passaged in the presence of increasing concentrations 
of the compound, until a resistance phenotype emerges. For the isolation of 
resistant mutants against the compounds discovered in this study, we decided to 
use SFV as a bio-safe surrogate for CHIKV, due to the cumbersome nature of the 
work, which would have to be done in a BSL-3 laboratory. Initially, a short 
passaging scheme of 8 h at MOI 0.1 was used. BHK-21 cells were infected with the 
wild type virus in the presence of the compound (10 μM for cerivastatin), which 
was present throughout the infection. Viral titers were analyzed after the first 
round of passaging and then adjusted for every subsequent passage to continue 
with approximately the same MOI of 0.1. Titers were evaluated after every fifth 
passage. Cerivastatin was the only compound for which this approach yielded 
results. 
 
After 10 rounds of passaging, we obtained a mutant showing complete resistance 
against cerivastatin, growing to titers as high as the untreated wild type virus. 
After plaque purification of several drug-resistant clones, subsequent sequencing 
showed a single point mutation in the E2 envelope glycoprotein. Recombinant 
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virus containing this mutation was generated and analyzed once again for 
phenotypic resistance. Interestingly, the untreated mutant virus grew to higher 
titers than the untreated wild type version. Nevertheless, in cerivastatin-treated 
samples, the mutant grew to even higher titers than the wild type virus under the 
same conditions (Fig. 7). Cerivastatin inhibits cholesterol biosynthesis by targeting 
the HMG-CoA reductase enzyme. Cholesterol has been implicated in the SFV life 
cycle for both fusion (330) and exit (331). Pre-treatment of  
BHK-21 cells for 2 h with 10 μM cerivastatin and prolonged treatment for another 
3 h, did not inhibit or enhance virus entry in the SFV-ts9-entry assay (data not 
shown). This may suggest that cerivastatin likely affects virus exit by 
downregulating cellular cholesterol levels. The specific role of this mutation in the 
E2 protein in viral exit and cerivastatin resistance is currently being analyzed.  
 
 
 
We did not observe phenotypic resistance for any of the other compounds using 
this short passaging scheme. In order to allow sufficient time for resistant mutants 
to emerge, a longer time window was used, where BHK-21 cells were infected at 
MOI 0.01 for 16 h (schematic layout in Fig. 5A; III). This approach gave better 
results as we could obtain partially drug-resistant mutants against abamectin, 
berberine and obatoclax. 
 
For abamectin, it took 30 rounds of passaging the wild type virus in the presence of 
increasing concentrations of the compound (beginning with 3 μM for 10 passages 
and 5 μM for passages 16 to 30) to obtain partially resistant mutants. Phenotypic 
analysis of plaque purified virus stocks revealed that the mutant resistant to 
abamectin also confers resistance to ivermectin (Fig. 8), which could be expected 
as these compounds are structural analogues and probably have the same modes 
of action. Sequencing this mutant revealed three non-synonymous mutations in 
viral nsP1, nsP2 and E2 proteins. The nsP2 mutation lies in the helicase domain. 
Fig. 7 Cerivastatin-resistant SFV 
mutant. BHK-21 cells were infected 
with wild type SFV and the SFV mutant 
containing the mutation in E2 at MOI 
0.1 for 8 h, in the presence or absence 
of 10 μM cerivastatin. Plaque assay 
titers from viral supernatants collected 
at 8 h p.i. Titrations were performed in 
duplicates. Representative data set 
from two independent experiments. 
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Interestingly, ivermectin was reported to target the flavivirus NS3 helicase at low 
micromolar concentrations (332) and was recently found to be active also against 
ZIKV (287). It would be interesting to assess the effect of ivermectin and abamectin 
on the helicase activity of alphavirus nsP2. Importantly, the isolation of mutants 
resistant to abamectin and ivermectin indicate that despite the high toxicity and 
low selectivity indices observed with these compounds, their antiviral activity is 
selective and can be separated from their toxicity. Ivermectin was also found to be 
effective against HIV, DENV (333) and VEEV (334), where the nuclear export of 
different viral proteins was blocked by ivermectin by disrupting their interaction 
with nuclear transport proteins, importins ? and ?. The VEEV capsid protein is 
known to impede nuclear trafficking and thereby affect host transcription by 
forming a complex with nuclear importin ?/?1 and exportin 1 (335). It would be 
interesting to know if ivermectin-resistant VEEV mutants could emerge and in 
which viral proteins would these mutations map to. The capsid protein of CHIKV is 
not known to exhibit this phenomenon, even though a putative nuclear localization 
signal has been identified (336). The Old World alphaviruses, including CHIKV 
mediate host shutoff through the nuclear shuttling of nsP2. Examining the nuclear 
localization of CHIKV or SFV nsP2 in the presence of ivermectin could shed more 
light on its mode of action.  
 
Using the same passaging scheme, passaging SFV in the presence of 3 μM berberine 
was sufficient to obtain a partially resistant mutant. We found two non-
synonymous mutations in one of the nsPs, which in combination conferred partial 
resistance against berberine, similar to the original resistant isolate (Fig. 9A). This 
result seems unexpected, when berberine has a predominant effect on the latter 
stage of the viral life cycle, by modulating MAPK signaling. This prompted us to 
analyze the ERK activation phenotype of the mutant. Interestingly, the resistant 
mutant showed increased ERK activation as compared to the wild type. Even 
though this activation is reduced by berberine, it is still as high as that observed for 
the untreated wild type sample (compare phospho ERK; lanes 3 and 6) [Fig. 9B; 
(316)]. 
Fig. 8 Abamectin and ivermectin-
resistant SFV mutant. BHK-21 
cells were infected with wild type 
SFV and the abamectin-resistant 
isolate at MOI 0.1 for 8 h, in the 
presence of 5 μM abamectin and 
ivermectin. Plaque assay titers from 
viral supernatants collected at 8 h 
p.i. Titrations were performed in 
duplicates. Representative data set 
from two independent experiments. 
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There could be two possible explanations for this particular observation: i) the 
mutations in the nsP region has increased the affinity of the viral enzymes to their 
substrates, allowing the virus to replicate more efficiently and at levels higher than 
the wild type, which then accounts for the increased ERK activation or ii) excess 
nsPs, which are not part of the viral replication complex, transiently interact with 
one or more components of the ERK pathway and that the activation of ERK 
and/or downstream targets could serve as a trigger for viral progeny release. 
These mutations could conceivably increase the affinity of such an interaction, 
allowing for increased ERK activation and thereby, increased viral egress. Indeed, 
the ERK signaling pathway has been implicated in the release of IAV particles from 
virus-infected host cells (262). These lines of research are currently being pursued. 
 
With obatoclax, which we discovered to be a fusion inhibitor for alphaviruses, 
partially resistant mutants could only be obtained after 30 rounds of passaging in 
the presence of 0.5 μM of the compound. Four common non-synonymous 
mutations were present in two different resistant viral clones – two in nsP2 (E46D 
and V601I) and two in the E1 fusion protein (L369I & S395R). Phenotypic analysis 
of recombinant viruses containing different combinations of mutations revealed 
that the nsP2 mutations or the E1 mutations alone could confer some amount of 
resistance. However, the combination of all four mutations together was most 
resistant, similar to the original resistant isolate. Unexpectedly though, the virus 
Fig. 9 Berberine-resistant SFV mutant. (A) BHK-21 cells were infected with wild type and 
recombinant SFV viruses containing different combinations of the nsP4 mutations and the 
original resistant isolate at MOI 0.01 with or without 3 μM berberine. 16 h p.i., cell culture 
supernatants were collected and plaque assay titers were determined for each treated and 
untreated sample. Data are presented as log reduction in viral titers as compared to the 
respective untreated virus samples. Representative data from two independent experiments. 
(B) HOS cells were infected with wild type SFV or recombinant virus containing both the nsP4 
mutations at MOI 10 with or without 5 μM berberine. 5 h p.i., cells were lysed and processed for 
Western blot analysis using antibodies against SFV nsP3, phospho-Akt, total Akt, phospho-Erk, 
total Erk and actin. Representative data set from two independent experiments. 
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containing only the L369I mutation also showed the same resistance profile as the 
combination of all four and the original resistant isolate. On the other hand, the 
virus containing only the S395R mutation showed only weak resistance (Fig. 5B; 
III). Mutations in the E1 fusion protein lend further support to our observations of 
obatoclax inhibiting virus fusion. Analyzing the E1 mutations in the SFV-ts9 entry 
assay, corroborated our results where SFV-ts9 virus containing only the L369I 
mutation had a seven-fold higher EC50 value for entry inhibition as compared to the 
wild type ts9 virus (Fig. 5D; III). Moreover, the ts9 viruses containing the E1 
mutations seemed to have increased fusogenic potential and gave higher luciferase 
signals (Fig. 5C; III), suggesting that these mutations may have been selected to 
confer the ability to fuse better and enhance the overall infectivity of the virus. In 
summary, these results indicate that the L369I mutation in the SFV E1 fusion 
protein is sufficient to confer partial resistance to obatoclax. However, we cannot 
exclude that the specific passaging conditions used to isolate these mutants could 
have led to mutations arising in nsP2. Similar to that observed with the 
cerivastatin-resistant mutant, all the recombinant viruses showed increased fitness 
and grew to higher titers as compared to the wild type virus (Fig. 5B; III). Earlier, 
it was shown both for CHIKV and HCV that serial passaging of the virus in cells led 
to increased viral fitness and reduced sensitivity to different viral mutagens and 
antiviral drugs (337, 338). 
 
It is generally considered to be quite difficult for escape mutants to arise when host 
processes required for different steps of the viral life cycle are targeted. However, 
recently there have been examples with IAV (339), CVB3 (340) and HCV (341) that 
escape mutants resistant to host-directed antivirals can arise, that somehow help 
circumvent the modulated cellular environment. Our new findings together with 
these previously published results suggests a paradigm shift from the long-held 
notion that antiviral resistance can emerge only if viral components or viral 
enzymatic processes are targeted. Our method of isolating drug-resistant mutants 
involves assessing viral titers of progeny virions that have accumulated over 
multiple replication cycles. Infection was performed at a low MOI of 0.01, allowing 
the possibility of escape mutants to arise. Other groups have used a different 
approach, where virus-induced CPE is observed after several days of infection in 
the presence of the particular antiviral compound (196, 210). The compounds 
presented in this thesis would not be tolerated in BHK-21 cells over such extensive 
periods. Nevertheless, using this approach of monitoring virus titers at intervals 
has enabled us to obtain fully or partially drug-resistant mutants for four different 
compounds. Notably, for the most effective inhibitors, extensive passaging was 
required, indicating a high barrier to resistance. 
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6. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The present study identifies some of the most effective potential candidate 
antivirals against CHIKV. It also highlights the importance of the drug 
repositioning strategy to obtain effective host-directed antivirals. 
Additionally, two of the compounds presented in this thesis (berberine and 
obatoclax) helped us to gain more insight into different aspects of 
alphavirus biology. 
 
The main highlights of this dissertation are as follows: 
 
a) The CHIKV replicon cell line is a viable and robust platform, amenable 
to automation and high throughput screening of antivirals targeting the 
replication phase of the CHIKV life cycle. In the future, the screening 
can be expanded to include larger chemical collections and compounds 
obtained from natural sources. 
b) Compounds abamectin and ivermectin were found to affect the early 
and replication stages of the viral life cycle. Ivermectin being in clinical 
use, it would be interesting to test the compound in a CHIKV mouse 
model. Furthermore, the resistant mutant obtained against this 
compound should be further characterized. 
c) CHIKV infection showed a robust activation of the MAPK signaling 
pathways. The molecular features of the viral components needed to 
trigger this activation remain to be determined. 
d) Berberine is an effective antiviral, which has a major effect on viral 
maturation/egress, through the modulation of one or more MAPK 
signaling networks. Most importantly, berberine is one of the few 
compounds to show reduction of CHIKV-induced inflammatory disease 
in a mouse model. Mutations that confer resistance to berberine 
enhanced activation of the ERK pathway. Further work needs to be 
done to elucidate the precise role of these mutations and the specific 
molecular target of berberine. 
e) Obatoclax is an anti-cancer drug that was revealed to neutralize the 
acidic environment of endolysosomes, thereby inhibiting viral fusion. 
Furthermore, mutation L369I in the SFV E1 fusion protein was enough 
to gain partial resistance against obatoclax.  
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CLUES 
 
ACROSS 
 
1.  Happens when a bug gets inside of you 
3.  This glowing protein makes studying viruses easier  
7. Energy currency in the cell  
12.  Used to compare and assess biological processes and experiments 
13. Clothing for viral genetic material 
17. Pursuit of testable knowledge through systematic study 
18. Often co-circulates with chikungunya and infects millions every 
year 
20. Novel fusion inhibitor described in this thesis 
24. Degree to which a substance causes damage to an organism 
27. Particle with a capsid shell and a nucleid acid core 
28. The species responsible for a million deaths every year 
29. The viruses in this thesis have this as a genetic material 
30. This thesis involved discovering more of these 
31. Country where chikungunya virus was first isolated in 1952 
32. Process of narrowing down a selection 
 
DOWN 
 
2.  Enveloped viruses enter a cell through this process 
4.  E3-E2 envelope proteins are cleaved by this enzyme 
6.  First line of information in the central dogma 
7.  Non-inflammatory joint pain 
8.  Designed to pinpoint a specific target 
9.  Abbreviation for a prototype virus belonging to the same family as 
chikungunya 
11.  Viruses hijack this cellular process to gain entry into the host cell 
14. Thousands of these were counted during the course of this thesis 
15. This technique was used the most for this thesis 
16. This genus was the first group of arboviruses to be classified 
17. This was the focal point of the second study in this thesis 
19. Viral envelope proteins do some crazy moves when exposed to this 
environment 
23. Final step in the viral life cycle 
25. Biological catalyst 
26. Investigative procedures that require plenty of optimization 
28. A cellular pathway studied in this thesis 
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